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The Global Foot-and-Mouth Disease Research Alliance 
The Global Foot-and-Mouth Disease Research Alliance (GFRA) comprises 16 international institutions 
actively engaged in Foot-and-Mouth Disease (FMD) research, as well as numerous partners, 
collaborators and stakeholders. The GFRA has five strategic goals aimed at expanding FMD research 
collaborations and optimizing use of resources and expertise: 
• Goal 1. To facilitate research collaborations and serve as a communication gateway for the 
global FMD research community. 
• Goal 2. To conduct strategic research to better understand FMD. 
• Goal 3. To develop the next generation of control measures and strategies for their 
application. 
• Goal 4. To determine social and economic impacts of the new generation of improved FMD 
control measures. 
• Goal 5. To provide evidence to inform development of policies for safe trade of animals and 
animal products in FMD-endemic areas. 
For more information, including current GFRA news and members, see http://www.ars.usda.gov/gfra/  
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Purpose of the report 
There are numerous FMD research organisations and experts. The broad focus of their research is 
driven by funding bodies, which in turn are directed by scientists, policy makers and non-governmental 
donors. It is important that each of these groups is aware of the current needs and gaps in FMD 
knowledge, technologies and research capacity. The purpose of this document is to provide 
appropriate information in these areas to facilitate an efficient and coordinated approach to global 
FMD research. 
Here, we provide a fully-referenced update of the research conducted on FMD and the FMD virus 
(FMDV) since the previous GFRA report in 2011. Alongside a review of the literature pertaining to 
priority research areas, current activities being undertaken at GFRA and EuFMD (European 
Commission for the Control of FMD) member institutions are included, alongside an analysis of the 
major gaps in knowledge and a summary of proposed next-steps. 
This information is presented in the context of the GFRA goals, with reference to the parent report, 
the 2010 Gap Analysis produced by The FMD Countermeasures Working Group in Buenos Aires, 
Argentina. The Gap Analysis provided a comprehensive summary of the priority research areas 
according to the state of knowledge in 2010, and therefore serves as a useful reference for the 
progress made in recent years. As well as a research update, it is our hope that this document will 
enable researchers to effectively target their work towards prioritized knowledge gaps, avoid 
duplication of efforts, and highlight opportunities for collaboration. 
A list of contributing institutes is provided in the Appendices. 
To cite this report: Robinson and Knight-Jones (2014) Global Foot and Mouth Disease Research Update 
and Gap Analysis, GFRA/EuFMD. http://go.usa.gov/cZgG9 
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Executive Summary 
In this report we combine literature review and expert consultation to evaluate global FMD research 
progress since 2011 and highlight remaining knowledge gaps, incorporating ongoing work from 33 
research institutes from around the world. 
Global needs: 
FMD is frequently listed as the most economically important disease of livestock in both developed 
and developing countries. Disease-free countries experience periodic FMD outbreaks and so must 
maintain their capacity for rapid detection and control. Some countries, particularly in South America, 
are successfully controlling and eradicating FMD through mass vaccination. However challenges 
remain in proving FMDV freedom in vaccinated populations and in the design, production and 
distribution of vaccines able to induce effective immunity to emergent field strains. In addition, many 
other endemic countries have no, or ineffective, control policies or programmes. In these cases there 
is an urgent need to understand the economic and social impacts of FMD within each region, and to 
determine whether or how FMD can be controlled by vaccination alone. Underpinning all this is the 
requirement for comprehensive knowledge of the virus itself, its interaction with host species, and 
how we can most effectively prevent its replication and spread within both individual animals and 
through populations. 
It is commonly accepted that FMD vaccines are not very stable and this has been historically blamed 
for their low levels of protection from FMDV in the field. While this principle is true, it has been 
highlighted in recent years that the manufacturing process itself warrants significant scrutiny moving 
forwards. A strong regulatory framework surrounding vaccine production is necessary to ensure 
antigen stability and to assure that maximum potency is realised under field conditions. These findings 
are discussed in more detail within the Vaccines section of this report. 
Recent developments: 
Since the last GFRA report, the USA has licensed a recombinant vector vaccine for use in cattle during 
an outbreak of FMD. Additional new vaccine technologies that address important gaps have also been 
transferred from GFRA research laboratories to vaccine manufacturers and are currently under 
development: a program of rolling out these new technologies to other parts of the world is likely to 
prove valuable in years to come. Studies of the interaction of the virus with the immune systems of 
various hosts are informing promising rational improvements to vaccine design and testing. Coupled 
with advances in manufacturing and quality control, we can be hopeful of improved outcomes from 
established vaccination programs in the medium term future. 
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In terms of molecular analysis, advanced genetic studies have improved understanding of FMD 
transmission with increasing relevance to field control. Development and scrutiny of mathematical 
models has enhanced outbreak preparedness and policy planning, although more ground testing is 
required. Novel molecular techniques promise to further reduce diagnostic costs and improve 
accessibility to high quality testing. 
 
Greater consideration is being given to commodity-based trade as a way of opening up FMD-free trade 
to poor farmers in wildlife endemic areas without the economic drain and ecological impact of 
zonation and enclosure of wildlife. 
Previously neglected, the importance of field epidemiology in the evaluation of FMD outbreaks and 
control programmes is being increasingly recognised. 
 
Research priorities by area: 
Controlling the disease 
Epidemiology 
Although the field of FMD modelling is progressing, validated best practices have not yet been 
established: rigorous ground testing of real time decision support tools, including those capable of 
estimating and comparing cost-effectiveness of different strategies will be required. The extent to 
which generic spread models can be used in different settings also needs to be determined. 
Further developments are required in defining appropriate surveillance methods, particularly those 
able to confirm of disease-free status in vaccinated populations. 
Clear guidance, knowledge sharing and evidence-based policy developments will be necessary to 
assist endemic countries to control FMD, with a focus on those possessing substantial smallholder 
farming sectors. At the same time, basic field epidemiology has been under-utilised in the evaluation 
of control programmes, particularly in endemic countries. A pressing question in this area is to what 
extent we can hope to control FMD by vaccination in the absence of effective biosecurity measures, 
which are notoriously difficult to enforce in some settings. 
The use of molecular and genetic techniques in combination with epidemiology is expanding as 
technologies become cheaper and more powerful. This progress must be supported, as major 
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breakthroughs in our ability to understand and ultimately control FMD could be imminent. The 
incorporation of these tools into practical disease control should also be encouraged. However, the 
ability to use models to predict severity and likelihood of transmission based on genetic data remains 
elusive. 
In the case of FMD-free countries, approaches for identifying high risk strains for incursion and 
estimating their impact should be developed. Efforts to maintain outbreak preparedness, including 
training, planning of control strategy and resource requirements need to be continued. 
Wildlife 
The need for improved understanding of the role of wildlife in FMD maintenance and transmission is 
evident. Characterising the features of infection and transmission in controlled studies and field 
studies of relevant species will be required to provide accurate information to inform policy on the 
role of wildlife in official FMD status. 
Socio-economics and international standards 
The full social and economic impact of FMD remains hard to estimate, which hampers effective design 
of control policies. In particular, in endemic regions with limited potential to access export markets, 
we currently know little of the impact of FMD and its control measures. High quality information would 
assist evaluation of FMD control options in order to mitigate disease impact. 
Social factors profoundly affect the effectiveness of monitoring and control policies. In particular we 
need to understand how best to use compensation as a means of maximising farmer participation in 
disease reporting and control. Furthermore, a wider appreciation of the regional social and cultural 
factors that affect compliance would be beneficial. 
Real-time economic models to guide disease control during outbreaks have been developed and must 
now be rigorously field tested. 
Vaccines 
The use of reverse genetics to engineer new FMD vaccines, such as inactivated leaderless FMD 
vaccines, viruses with improved stability and culture adaptation, and FMD virus-like particles, has the 
potential to revolutionise the safe and cost-effective production of effective FMDV vaccines. However, 
careful evaluation of novel vaccines is needed with a particular focus on their efficacy in species other 
than cattle and their effects on non-humoral aspects of the immune response. 
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Several novel adjuvanting or vectoring strategies for various FMD vaccines also show promise but will 
require further testing in a range of species under physiological challenge conditions. Whilst 
convenient and cheap, the use of murine systems should be explored with extreme caution in light of 
accumulating data on relevant differences between their immune systems and those of natural FMD 
target species. In addition, the importance of qualitative aspects of the response to FMDV infection 
and vaccination, such as the characteristics of non-neutralising antibodies, or the immunoglobulin 
isotype ratio induced, must be recognized, and these parameters should be included during the 
evaluation of novel adjuvants or vaccines. To provide meaningful reference, conventional vaccines 
should be included alongside any novel approach in all studies. 
Improved methods enabling the rapid and effective purification of FMDV for conventional vaccine 
production are under development which, if rolled out widely, could improve control in endemic areas 
within a relatively short time. 
Some studies have begun to indicate possible ways of using needle-free strategies to induce protective 
mucosal responses to FMDV vaccines, but further study of mucosal immunity in target species 
(perhaps requiring the development of additional tools), both in general and in relation to FMD, will 
be required to realise the potential of this strategy. 
Predicting vaccine matching with emerging field strains remains challenging. 
The control of FMD in endemic regions would be markedly assisted by improving the formulation of 
quality controlled vaccines and reagents to extend shelf life and reduce cost, thereby potentially 
increasing both availability and efficacy. More broadly, standardised independent quality assurance 
should be used by all FMD vaccine production facilities. 
Despite much effort, reliable immune correlates of protection remain to be identified. An absence of 
standardised approaches to vaccination and challenge during early vaccine development is likely to 
have contributed to this problem, and should be addressed as a matter of urgency, ideally in 
collaboration with the OIE and other international bodies to ensure widespread uptake of resulting 
recommendations. The definition of a common protocol and minimum set of basic standards for such 
experiments would have dramatic impacts on our ability to compare novel vaccination strategies 
carried out at different sites, and provide a way of understanding which approaches warrant further 
study and which should be discarded. The current haphazard use of different protocols under diverse 
conditions with individually selected readouts risks sub-optimal use of time and resources and must 
be considered a high priority for change. 
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Biotherapeutics 
In 2010, the use of adenovirus to vector interferon (IFN) α (Ad5- IFNα) into hosts and induce short-
lived non-specific protection against FMDV appeared promising. It now seems that Ad5-IFNα alone is 
insufficiently potent for use in outbreak situations. However, studies combining Ad5-IFNα with an 
additional immune stimulator show promise, as does Ad5 encoding an IFN-stimulating transcription 
factor in place of IFNα. Substituting Type III IFN into the Ad5 vector appears more effective, particularly 
in cattle, and warrants further investigation. 
An area of urgent unmet research need is the potential interaction of immune-modulating 
biotherapeutics with the response to vaccination. Before use in the field, we must know how 
expression of large amounts of these innate immune cytokines affects both qualitative and 
quantitative aspects of the immune response in target species. For example, high levels of IFNα can 
adversely impact the magnitude of T cell responses, which in the case of FMD vaccination, could 
preclude the formation of sufficient immunity to confer protection from disease. This has so far been 
almost completely neglected in the literature. More generally, the integration of biotherapeutics into 
existing emergency measures similarly remains to be achieved. 
Non immunological, small molecule inhibitors of FMDV 3Cpro have been identified, but remain to be 
tested in target species in vivo. 
RNA interference-based strategies are also being explored, though their suitability for upscaling to the 
levels required in outbreak situations has yet to be assessed. 
Disinfectants 
While published literature has focused on the environmental impact of existing disinfectant use in 
recent outbreaks, ongoing work, particularly at the Plum Island Animal Disease Center (PIADC), aims 
to develop standardised disinfectant efficacy test methods, to assess activity of antimicrobial 
pesticides against FMDV, and to define optimal conditions of use for new and established 
disinfectants. 
Diagnostics 
Continued development of molecular and genetic technologies combined with novel analytical 
techniques will benefit many areas of FMD research and understanding. Production of effective pen-
side tests and increasing the usability and affordability of various FMD diagnostics for laboratories 
with limited resources would offer significant benefits to endemic regions in particular. 
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Improved diagnostics for SAT strains are still required, as are better tests to support DIVA 
(Differentiation of Infected and Vaccinated Animals) and for vaccine matching. Investigation of air 
sampling technologies is ongoing. 
Further development, validation and standardisation of methods for measuring post-vaccination 
population immunity are required. 
Understanding the virus 
Pathogenesis 
Our understanding of FMDV persistence has been revolutionised by finding that retention of virus in 
the lymph node appears to be more the rule than the exception, even in species not thought capable 
of retaining live virus, such as swine. What remains to be seen is whether this phenomenon is primarily 
to the advantage of host or pathogen. 
Understanding early events during infection has been hampered historically by the common use of 
non-physiological routes of challenge with the virus. Data now show that widespread adoption of 
more relevant routes of infection for laboratory studies is both feasible and desirable. Standardisation 
and universal acceptance of this approach would be enormously beneficial. 
Beyond expression of integrins, evidence of other determinants of susceptibility at the cellular level 
have gained interest in recent years and should be pursued. 
Factors underpinning genetic resistance and age-related susceptibility to FMDV infection warrant 
investigation. 
Determinants of the extent of the role of wildlife species in field conditions during outbreaks should 
be defined with the support of laboratory controlled infections to enable full understanding of the 
disease in epidemiologically relevant non-agricultural species. 
Immunology 
New knowledge on the bovine immunoglobulin response requires interpretation for its relevance to 
FMDV infection and vaccination in natural FMDV target species. 
The importance of non-neutralizing antibodies in the response to FMDV has become apparent, 
particularly in terms of interactions of antibody-bound virus with immune cells. We now need to 
define the roles of these immune complexes in vivo in target species to enable their exploitation. 
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Regulatory gamma-delta T cells appear to play a previously unappreciated role in the response to 
vaccination of cattle. Comparable experiments should be undertaken in other target species to 
understand the impact of this cell type to FMD vaccination in broader terms, particularly in light of 
new data highlighting the importance of T cell responses for optimal vaccine-induced immunity. 
Similarly, novel approaches have revealed that CD8 T cell stimulation may also be a desirable outcome 
of vaccination, but its potential remains unexplored outside of swine. 
The neonatal immune systems of FMDV target species remain far less well characterised than their 
adult counterparts. Further study of neonatal immunity, with particular reference to the T cell 
compartment, and in conjunction with characterisation of FMDV vaccine and adjuvant responses is 
required. 
Qualitative hallmarks of effective adaptive immunity to FMD vaccines and infection are being 
uncovered. Understanding how to use this knowledge in a more comprehensive approach to vaccine 
design could prove valuable. Further study to determine how to achieve optimal IgG class ratios and 
increase immunoglobulin avidity should inform development of improved vaccines, particularly where 
cross-protection is a priority. 
Mucosal immune responses remain relatively under-studied in target species. Robust techniques 
should be developed and applied to understand how mucosal and systemic immunity combine to 
provide effective protection following vaccination and during infection. 
Molecular biology 
The multiple and varied ways in which FMDV manipulates the host immune system are becoming 
evident from molecular studies that should serve to both validate and direct design of novel 
biotherapeutics. 
Substantial data indicate that FMDV 3A warrants further investigation as a determinant of both 
virulence and host tropism, but an emphasis on experimentation in natural host species is required to 
move forwards. 
Exploitation of precise, quantitative, high-throughput molecular techniques to study FMDV holds 
great promise for advances in understanding of pathogenesis at the cellular level. Their future 
application to primary cells or more physiologically-relevant cell lines, combined with careful 
experimental design, will be required for this promise to be realised. 
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Considering recent advances in our molecular understanding of FMDV’s interactions with the host 
interferon response, we now need to establish to what extent we can link molecular findings with 
whole organism responses to natural infection. As a starting point, some of the experiments that have 
been carried out in immortalised cell lines should be repeated in cell lines and/or primary cells from 
relevant target tissues of natural host species. 
New research tools and approaches 
Large animal experimentation for FMDV is necessary, but coupling this approach with appropriate in 
vitro and small animal models of the disease has the potential to expedite research progress and 
reduce the number of large animals needed. However, the challenge of developing and validating the 
“right” model remains. In parallel, reagent/method development to enable in-depth study of the 
immune systems of target species, particularly the mucosal compartment, would facilitate advances 
in FMDV pathogenesis and vaccine science. 
The connection of internationally-recognised centres of expertise in FMD with local research institutes 
in affected regions will enable effective transfer of knowledge and expertise to smaller centres and 
ensure a standardized approach to the characterisation of new isolates in common or locally-relevant 
host species. Some institutes are pioneering this approach, which has the potential for widespread 
benefit to the FMD research community. Opportunities to extend and replicate this model should be 
sought and supported. 
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Abbreviations 
AHL-NZ: Animal Health Laboratory – New Zealand 
AHAW: Animal Health and Welfare panel (of the European Union) 
ANSES: Agence Nationale de Sécurité Sanitaire de l’alimentation, de l’Environnement et du travail 
(National Agency for Food, Environmental and Occupational Health Safety), France 
APHIS: Animal and Plant Health Service, USDA, United States of America 
ARS: Agricultural Research Service, USDA, United States of America 
BVI: Botswana Vaccine Institute, Botswana 
CAAS: Chinese Academy of Agricultural Sciences 
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Research Center), Belgium 
COX-2: Cyclo-Oxygenase 2 
CSIRO-AAHL: Commonwealth Scientific and Industrial Research Organisation, Australian Animal 
Health Laboratory, Australia 
DC: Dendritic Cell(s) 
DIVA: Differentiation of/Differentiating Infected from Vaccinated Animals 
DHS: Department of Homeland Security, United States of America 
DNA: Deoxyribonucleic Acid 
DTU: Danmarks Tekniske Universitet (Technical University of Denmark), Denmark 
EFSA: European Food Safety Authority 
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EU: European Union 
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FMD: Foot-and-Mouth Disease 
FMD-DISCONVAC: Development, Enhancement and Complementation of Animal-sparing, FMD 
Vaccine-Based Control Strategies for Free and Endemic Regions 
FMDV: Foot-and-Mouth Disease Virus 
GFP: Green Fluorescent Protein 
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ODN: Oligodeoxynucleotides 
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PCR: Polymerase Chain Reaction 
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PGE2: Prostaglandin E 2 
PPRV: Peste des Petits Ruminants Virus 
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Background 
 
In August 2010, the FMD Countermeasures Working Group was created to bring together a selection 
of leading authorities in the field of FMD. With the support of the GFRA and the Instituto Nacional de 
Technologia Agropecuaria (INTA) of Argentina, they conducted an analysis of current knowledge of 
the disease and its control in both epidemic (predominantly the US) and endemic situations. At that 
time, the group identified several major obstacles to effective prevention, detection and control of 
FMD, including: 
1. Poor and inadequate education and training of veterinarians and livestock producers in 
detecting early signs of FMD. 
2. Lack of validated commercial pen-side test kits for disease control. 
3. Failure of serologic methods to determine status (infected, uninfected) in some vaccinated 
animals. 
4. Absence of a surveillance system for early recognition of signs, or to find evidence using 
antigen detection, antibody, or virus detection. 
5. Lack of reliable comprehensive international surveillance systems to collect and analyse 
information. 
6. Current models have not been designed to evaluate in real-time the cost-effectiveness of 
alternative control, surveillance, and sampling strategies. 
7. Several aspects of FMD epidemiology and transmission still have to be uncovered, including 
the influence of viral factors that affect viral persistence, emergence, competition, 
transmission, and spread of FMD virus strains. 
8. There are no FMD vaccines permitted for distribution and sale in the US 
9. At present, there is no rapid pen-side or field-based diagnostic test for FMD control during a 
disease outbreak that has been validated in the field as “fit for purpose.” 
10. There is a need for better analytical tools to support decisions for FMD control. 
 
These obstacles were further broken down into priority research knowledge gaps, and in this report 
we will present recent progress towards filling those gaps. We will also highlight points that remain to 
be addressed, and identify new targets for research that have emerged as a product of improved 
understanding and/or changing needs since 2010. 
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Report approach 
This report summarises recent completed and ongoing global FMD research and thereby identifies 
current knowledge gaps. A literature review was conducted to identify recent published FMD 
research. This was based on a PubMed search using the search terms “foot and mouth” but not “hand, 
foot and”, published between June 2011 and June 2014. This returned a total of 505 relevant peer-
reviewed manuscripts that could be approximately allocated to research topic areas as shown in Table 
1. 
Research Category Papers (n) 
Epidemiology 116 (23%) 
Vaccines 94 (19%) 
Pathogenesis 74 (15%) 
Molecular biology 57 (11%) 
Diagnostics 55 (11%) 
Immunology 50 (10%) 
Policy, preparedness and trade 38 (8%) 
Wildlife 19 (4%) 
Vaccine evaluation 
 (quality, efficacy, effectiveness) 16 (3%) 
Other 15 (3%) 
Economics 14 (3%) 
Biotherapeutics 13 (3%) 
Total 505 (100%) 
Table 1: FMD peer-reviewed publications June 2011-June 2014 sub-divided by topic area. 
All member institutes of the GFRA and EuFMD collaborators were also contacted and given the 
opportunity to contribute updates on their recent, ongoing and future FMD research activities. 
Responses were received from 33 institutes (see appendix - Contributing Institutions & Financial 
Support), distributed as follows: 
• Europe – 10 institutes (30%) 
• North America – 5 institutes (15%) 
• South America – 2 institutes (6%) 
• Asia – 6 institutes (18%) 
• Africa – 8 institutes (24%) 
• Australia/New Zealand – 2 institutes (6%) 
Published literature and research updates were then summarised for each area of FMD research and 
evaluated in the context of the goals identified in the 2010 Gap Analysis. Any unmet goals from 2010 
19 
 
were noted and new goals were also highlighted in order to provide a comprehensive account of the 
most pressing topics in need of research as of June 2014.  
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Introduction 
Although a disease of low overall mortality, FMD places a huge burden on both individual livestock 
keepers and national economies (Fogedby 1962, James and Rushton 2002, Sutmoller, Barteling et al. 
2003, Knight-Jones and Rushton 2013). It is a viral disease (family: Picornaviridae, genus: Aphthovirus) 
affecting cloven-hoofed animals, the epidemiologically and economically most important hosts being 
cattle, water buffalo, pigs, sheep and goats. As well as infecting agricultural species, FMDV can be 
maintained within populations of certain wildlife species, such as African buffalo and wild boar, which 
act as a reservoir of virus capable of transmitting the virus to livestock (Alexandersen, Zhang et al. 
2003, Alexandrov, Stefanov et al. 2013). 
There are seven different FMD serotypes (O, A, Asia-1, SAT-1, SAT-2, SAT-3 and C) which tend to exist 
in regional virus pools, within which virus strains tend to circulate (Figure 1). 
 
Figure 1: The conjectured status and distribution of FMD, showing regional virus pools (Hamond 2012). 
Serotype C has not been detected since 2004. 
Following infection, FMDV replicates in the animal for between 2 and 21 days before the onset of 
clinical signs, during which time large amounts of virus may be shed into the environment. Typical 
signs of infection include vesicular lesions on the feet, mouth, tongue and udder, accompanied by 
fever and weight loss. In young animals, the virus can cause fatal myocarditis. Even when an animal 
recovers from infection, long-term morbidity is common, and up to 50% of recovered ruminants 
continue to harbour live virus in the absence of clinical signs. There is therefore the potential for these 
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carrier animals to transmit FMDV to other livestock, and for this reason their existence has far-
reaching consequences for both the epidemiology of FMD and for trade with epidemic-recovered or 
endemic countries. 
Thus the impacts of FMDV can be understood on two levels: 
Direct 
1. High mortality in young stock. 
2. Reduced productivity including milk yield, fertility, growth rate, and traction power (where beasts 
of burden are used). 
3. Change in herd structure with a need to maintain more breeding adults for the same level of 
output (for example, milk, young-stock, meat). 
Indirect 
1. Cost and impact of disease control including movement restrictions, market closures, vaccination 
costs and culling. 
2. Control measures may impact on other industries including tourism. 
3. Loss of access to lucrative livestock and livestock product export markets. 
4. In endemic regions, FMD prevents the use of high productivity breeds that are more susceptible 
to the disease. 
Countries or zones are divided into three categories depending on their FMD status: FMD-free without 
vaccination, FMD-free with vaccination and endemic. Each category will feel the threat and impact of 
FMD differently, and so have different priorities in terms of research, prevention and disease control. 
For FMD-free countries/zones the emphasis of management is on reducing the risk and impact of virus 
incursions. Risk reduction is intimately linked to FMD incidence in both neighbouring and trade-
partner countries, and is determined largely by a region’s ability to manage the flow of animals and 
their products from these countries. Should an incursion occur, early detection is crucial, followed by 
rapid implementation of an effective control strategy. Once the outbreak has been controlled the 
focus moves to surveillance, which is required to identify remaining sources of infection, to prove 
freedom from disease, and eventually to regain international trading rights. Vaccination may be used 
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to assist outbreak control and therefore vaccine banks must be constantly maintained and frequently 
updated to maximise efficacy against currently-circulating strains. 
Countries that are FMD-free with vaccination have similar interests, but may have different priorities 
in terms of vaccination, with long-term immunity being of particular relevance. A dependence on 
regular vaccination brings several problems of its own: differentiating infected from vaccinated 
animals (DIVA) by means of serology remains a challenge, and vaccinated animals may become sub-
clinically infected thereby potentially masking an outbreak situation. In addition, the financial burden 
of vaccine provision, distribution and repeated gathering of livestock for inoculation is considerable. 
In endemic countries there is an urgent need for potent, quality-assured vaccines that induce longer 
immunity and can be produced in vast quantities, at low cost. As the majority of FMD research is 
conducted in more affluent countries, which are also often FMD-free, our knowledge of controlling 
epidemics is considerably greater than that of managing endemic FMD. Accordingly, in these regions, 
control strategies are often sub-optimally designed and poorly implemented. This is a pressing 
concern as FMD production losses have the greatest impact on the world’s poorest countries, where 
more people are directly dependent on livestock (Figure 2). 
The annual global impact of FMD in terms of visible production losses and vaccination costs in endemic 
regions alone amounts to between 6.5 and 21 billion USD, while outbreaks in FMD-free countries and 
zones cause additional losses of >US$1.5 billion a year (Knight-Jones and Rushton 2013). FMD is 
frequently listed as the most economically important disease of livestock in many developed and 
developing countries (Perry and Randolph 2003, Perry and Rich 2007, Perry and Rich 2007, Perry, 
Sones et al. 2007, Perry and Grace 2009, Rushton and Knight-Jones 2012). 
Vaccination is now a component of every control program for FMD, whether in response to endemic 
disease or an incursion into a previously FMD-free region. However, most countries remain reliant on 
FMD vaccines that have changed relatively little over the last 30-40 years; they provide limited cross-
protection against different viral strains, fail to induce sterile immunity and require regular boosting 
to maintain protective efficacy. The vaccines themselves are expensive and risky to produce, requiring 
the culture of large amounts of live virus for inactivation, and, once formulated, need cold-chain 
storage to point-of-use. Extensive research into the design of novel vaccines and improvements to 
current approaches is beginning to address these issues (see section on Vaccines within Controlling 
the Disease).  
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Figure 2: Upper panel – August 2014, OIE global FMD status, with recent outbreaks in free zones identified. 
Middle panel - global burden of FMD in cattle in 2008 (burden in sheep and goats has a similar distribution). Prevalence 
index based on estimates of incidence, population distribution and other risk factors, adapted from (Sumption, 
Rweyemamu et al. 2008). Note progress in South America since 2008 [compare with upper panel]. 
Lower panel - density of poor rural livestock keepers from (Thornton, Kruska et al. 2002). Central America, parts of South 
East Asia and some areas in South America are the few exceptions where FMD was not present in poor livestock keeper 
populations. 
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The long-standing challenges to effective control of FMD reflect gaps in our knowledge of the virus 
and the disease. The events immediately following exposure of the host to the virus remain poorly 
characterised, as do aspects of host species’ immune systems and responses to the virus. How the 
virus’ tropism for different host species, individual animals and tissues within those animals is 
determined, is as yet unclear. Accordingly, many of the gaps highlighted in this report are within the 
areas of basic research into FMDV-host interactions at the molecular and cellular level. Coupled with 
detailed immunological studies in host species, these studies will enable rational design of improved 
vaccines formulated in a way that will facilitate their widespread use. As ongoing research projects 
are completed and followed by appropriately conducted studies in the areas highlighted here, we 
believe that there is every reason for optimism that our ability to control FMD will be substantially 
improved in the near future. This will, however, depend entirely on significant funding to maintain 
and advance the most promising research and development programs. 
In the following section we present a review of recent literature on FMD research and updates of 
ongoing work at GFRA and EuFMD institutes. To aid understanding, this information is divided into 
research topic areas, which themselves fall under the broader headings of either Controlling the 
Disease or Understanding the Virus. 
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Controlling the Disease 
Global FMD update: 2011-14 
The global FMD landscape has undergone several shifts since publication of the 2011 GFRA report. 
FMD SAT-2 outbreaks in North Africa and the Middle East caused significant losses and an 
international crisis in 2012, which was exacerbated by limited efficacy of the SAT-2 vaccine used. In 
2014, serotype O outbreaks in non-endemic regions of North Africa have been a cause for concern: in 
Southern Africa, outbreaks continue to occur within long-established, and previously successful, FMD 
control programmes that are based on zonation, vaccination and exclusion of FMD endemic wildlife. 
This has been disastrous for the beef export industry. 
The most recent FMD outbreak in the EU occurred in 2010/11, and was associated with wild boar 
infected with an Asia-1 strain from Turkey. This outbreak highlighted the previously-underestimated 
role of wildlife in this region and revealed shortfalls in vaccine matching and potency of some vaccine 
banks in FMD-free countries. Sporadic outbreaks continue to be reported in Russia. 
In Asia, large outbreaks have occurred in the previously FMD-free countries of Japan (2010/11) and 
South Korea (2010/11 and 2014) as a result of virus spill-over from epidemics within neighbouring 
endemic countries. Encouragingly, the Philippines have now achieved FMD-free status, which should 
have considerable benefits for the region. India and China have both prioritised FMD control and are 
vaccinating on a large scale; this is a considerable challenge given the scale of quality-controlled 
vaccine production required and the necessity for high coverage across vast areas. Greater still is the 
challenge of implementing acceptable, yet effective, movement controls and biosecurity measures in 
smallholder systems. 
There is cause for optimism in South America, where no FMD outbreaks have been reported since 
early 2012, with more and more countries/zones obtaining official FMD-free status. The know-how 
amassed within these control programmes could be utilised by those elsewhere attempting to control 
the disease through mass vaccination, but effective means of disseminating this valuable knowledge 
remain to be developed. 
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Epidemiology and control 
From the 2010 Gap Analysis: 
The priority aim was to produce analytical tools to support decision-making, with an emphasis on 
developing: 
1. Anomaly detection methods to identify outlier events.  
2. Prediction models for identification of genetic variants of viruses, to predict severity, duration, 
and likelihood of transmission of disease, and to evaluate the degree of success of control and 
prevention interventions. 
3. Epidemiological models that project spread of disease in a defined region under various 
control strategies and that can be used in developing disease control programs and for active 
surveillance sampling. 
Literature review 
Improved models 
Since the 2011 report, 111 studies of FMD epidemiology have been published, almost half of which 
described advances in mathematical modelling. Most used transmission models to predict the 
consequences of outbreaks in FMD-free countries, estimate resource requirements and compare 
different control options, particularly the impact of vaccination [see section on control of epidemics 
in disease free countries] (Backer, Engel et al. 2012, Backer, Hagenaars et al. 2012, Hagerman, Ward 
et al. 2013, Garner, Bombarderi et al. 2014). One study combined data on FMDV ecology and 
maintenance with a modelling approach to estimate the relative roles of domesticated animal species 
compared to deer and wild boar, with reference to a Bulgarian outbreak in 2011 (Dhollander, Belsham 
et al. 2014), revealing the potential for wildlife hosts in similar climatic zones to contribute 
substantially to the spread of disease. 
Several papers used risk analysis to assess the chance of a FMDV incursion when importing livestock 
and commodities. Simulation of theoretical outbreaks in France revealed the potential positive impact 
of improved surveillance protocols, and in particular, the importance of having specialist veterinarians 
available to support diagnosis as soon as FMD was suspected (Rautureau, Dufour et al. 2012). 
Models developed for epidemics are largely not appropriate for use in endemic situations, but 
developing models to deal with the complexity of endemic FMD is enormously challenging. A recent 
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study identified important factors influencing control in a vaccinating endemic region, suggesting that 
duration of natural immunity, rate of vaccine induced antibody waning, and the rate of disease re-
introduction are key to the success of vaccine strategies. Moreover, the efficacy of prophylactic, as 
opposed to ring, vaccination was highlighted in this model, as was the importance of the duration of 
natural immunity in determining size and frequency of disease outbreaks (Ringa and Bauch 2014). 
A few publications compared and reviewed the suitability of different modelling strategies (Sanson, 
Harvey et al. 2011, Tildesley and Ryan 2012, Flood, Porphyre et al. 2013, Halasa, Boklund et al. 2014); 
a retrospective evaluation of model performance illustrated the impact of poor control decisions 
based on models designed using inaccurate data (Mansley, Donaldson et al. 2011), highlighting the 
importance of precise knowledge of pathogenesis and transmission in different species under varied 
conditions. 
New data to inform better modelling 
 Consideration of the combined outcomes of various studies by meta-analysis, as illustrated by 
(Bravo de Rueda, Dekker et al. 2014) supports the need for improved parameterisation and the 
development of more robust epidemiological models. 
Model accuracy is limited by input data quality, which in turn comes from both laboratory studies and 
from field epidemiology. Field studies constituted about a quarter of FMD epidemiology publications, 
largely conducted in countries where FMD is endemic. Several were descriptive or risk factor studies 
based on FMD sero-surveys of countries in the early stages of FMD control (Dukpa, Robertson et al. 
2011, Abubakar, Arshed et al. 2012, Ayelet, Gelaye et al. 2012, Dukpa, Robertson et al. 2012, Kibore, 
Gitao et al. 2013), sometimes looking at wildlife (Bolortsetseg, Enkhtuvshin et al. 2012, Alexandrov, 
Stefanov et al. 2013, Jori, Caron et al. 2014, Mkama, Kasanga et al. 2014). Consistent, rigorous 
sampling coupled with standardised design and analysis would allow clearer estimation of the burden 
of disease and accurate comparison of that burden between different sero-surveys.  
Evaluation of efficacy of different control methods in endemic countries: 
Field studies are starting to be used to assess vaccine performance (Brito, Perez et al. 2011, Knight-
Jones, Bulut et al. 2014). A recent meta-analysis of 28 studies estimating the efficacy of vaccination in 
China suggested that more than 70% of animals from government-targeted species were adequately 
protected against serotypes Asia-1 and O (Cai, Li et al. 2014).  
 Guidance on target vaccine coverage and efficacy should be updated using modern approaches.  
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 The ability to monitor population immunity would be enhanced by the identification of stronger 
correlates of protection, above/more reliable than the virus neutralisation test (VNT). Current 
knowledge of correlates is largely limited to the first month after vaccination with homologous strains. 
Within a vaccination programme, long term protection against heterologous strains is important. 
 Improved tests to detect FMDV carriers are required, isolation of live virus from oro-pharyngeal 
region is time consuming and unreliable. 
Surveillance 
Several studies also assessed surveillance data (Madin 2011, Kasanga, Sallu et al. 2012) and its use in 
disease management (Willeberg 2012). In a field based surveillance study, a combination of non-
structural protein (NSP) antibody surveillance of pigs at livestock markets followed by clinical 
investigation was used to identify FMD infected farms in Taiwan (Chen, Lee et al. 2011). An important, 
yet hard-to-quantify issue is behavioural factors affecting disease reporting and control. Attempts 
have been made to understand the barriers to compliance for farmers in Texas (Delgado, Norby et al. 
2012), and Bolivia (Limon, Lewis et al. 2014). Taken together, these studies effectively highlighted the 
differences between farming populations in the two countries, and the importance of understanding 
local cultural and social factors that influence the agricultural community’s motivations to report FMD 
outbreaks. 
Molecular studies 
Substantial improvements in our ability to accurately model FMD have come via molecular 
epidemiological studies that have been able to link outbreaks caused by closely related viruses 
(Ahmed, Salem et al. 2012, Hui and Leung 2012, Hall, Knowles et al. 2013, Wright, Knowles et al. 2013), 
as well as estimate the likely roles of various transmission routes in both the UK 2001 (Morelli, 
Thebaud et al. 2012) and Bulgarian 2011 outbreaks (Valdazo-Gonzalez, Polihronova et al. 2012).  
Challenge studies 
Challenge studies have refined knowledge of key epidemiological parameters including: the point of 
onset of clinical signs during infection in cattle (Chase-Topping, Handel et al. 2013); the relationship 
between onset of clinical signs and the FMD transmission window in cattle (Charleston, Bankowski et 
al. 2011); the ability of sheep to transmit the virus to cattle [“the results indicated that in a mixed 
population of sheep and cattle, sheep play a more limited role in the transmission…than cattle.” (Bravo 
de Rueda, de Jong et al. 2014)]; the potential of wild boar (Breithaupt, Depner et al. 2012), or buffalo 
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(Madhanmohan, Yuvaraj et al. 2014) to act as hosts; and the optimal use of full-genome sequencing 
to understand transmission pathways during epidemics (Juleff, Valdazo-Gonzalez et al. 2013, Orton, 
Wright et al. 2013). Field data have also been combined with transmission experiments (Hagenaars, 
Dekker et al. 2011, Sanson, Gloster et al. 2011) and modelling approaches (Chis Ster, Dodd et al. 2012) 
to generate improved data for incorporation into next-generation models. 
Descriptive studies 
Other field epidemiology papers described eradication campaigns and factors contributing to success 
(Windsor, Freeman et al. 2011, Naranjo and Cosivi 2013). Such reports are useful to endemic countries 
attempting improved FMD control, where informed control policy guidance is sometimes limited. 
Quantitative evaluations of the progress and effectiveness of ongoing control programmes in endemic 
countries were few and far between and would be similarly valuable in informing future decision-
making. 
Similarly important are the descriptions of recent outbreaks (Muroga, Hayama et al. 2012, Cho and 
Chu 2013), including lessons learned and reviews of regional or national FMD situation, including 
disease epidemiology (Swallow 2012) and control strategies (Parent, Miller et al. 2011, Leon 2012, 
Ding, Chen et al. 2013, Ferguson, Cleaveland et al. 2013, McReynolds and Sanderson 2014). 
 Facilitating the sharing of knowledge between those with recent experience of FMD eradication in 
endemic countries and individuals responsible for similar attempts in their own nation would minimise 
the repetition of mistakes and likely improve overall outcomes.  
 A problem for most endemic countries is that they are unable to improve biosecurity and 
movement restrictions, given the small holder systems that predominate with dependency on 
common grazing and frequent trading of livestock to provide income for many people. More potent 
vaccines may control FMD despite poor biosecurity, however, this has yet to be assessed. 
 
Breed resistance 
Antibody response to commercial tetravalent vaccine was significantly impacted by breed (Di 
Giacomo, Brito et al. 2013). Breeding for both productivity and resistance to FMD may represent a 
complimentary approach to conventional control measures in endemic regions. One study provides 
evidence that MHC type can determine clinical protection from disease following inoculation of 
virulent FMDV in naive Wanbei cattle (Lei, Liang et al. 2012). 
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Control of epidemics in disease-free countries 
In terms of FMD control policy, much of the efforts of FMD-free countries is concerned with minimising 
the risk of a virus incursion and minimising the impact of an outbreak should one occur. This comprises 
several different aspects, including identifying high risk activities likely to increase the chance or 
severity of an outbreak, predicting how an outbreak is likely to behave and deciding on the most 
effective control policy for a range of situations. Contingency planning should ensure that resources, 
skills and legislative capacity are sufficient. Ground testing, including simulation exercises, should be 
performed to assess control measures for efficiency, feasibility, compliance and disruption to the 
farming sector and other areas of the economy. 
Modelling 
Predictions about outbreaks and control measures, used to inform contingency plans, have become 
heavily reliant on modelling. This is due to the complex nature of disease transmission within the 
livestock population [also mentioned in the epidemiology section].  
For example, prediction models have suggested that the final scale of an outbreak is strongly 
correlated with the situation after two weeks, and this could inform decisions on whether or not to 
scale up control efforts at this early stage of an outbreak (Halasa, Willeberg et al. 2013). Elsewhere 
fault tree analysis has been used to identify potential weaknesses on control strategy (Isoda, Kadohira 
et al. 2013).  
Vaccination 
The role of vaccination has been modelled extensively. In the Netherlands, it was estimated that in 
areas of high farm density, ring vaccination would halt an epidemic as rapidly as pre-emptive culling, 
whilst dramatically reducing the number of farms culled. However, if large numbers of pig farms 
require vaccination, vaccine supplies will be insufficient as pig farms contain many more individuals 
than cattle farms. Not vaccinating pigs did not appear to impact significantly on epidemic size (Backer, 
Hagenaars et al. 2012). However, findings from models are likely to be specific to the setting 
evaluated. The same model suggested that in areas of low farm density, culling detected farms only, 
without vaccination, would be sufficient, assuming infected farms are detected 6-10 days for cattle 
and pigs, with lower detection rates in sheep and goats, and culling taking place a day after detection 
(Backer, Hagenaars et al. 2012). These results were also used to assess the most efficient post-
outbreak surveillance strategy (Backer, Engel et al. 2012). In Switzerland, vaccinating a wide area 
around affected herds was considered to only be beneficial during a widespread, non-localised 
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epidemic, while failure to restrict movements and delayed culling were deemed critical, highlighting 
the importance of preparedness and the capacity of veterinary services (Durr, Fasel-Clemenz et al. 
2014). A simulation of FMD in Germany found widespread ring vaccination preferable to pre-emptive 
culling (Traulsen, Rave et al. 2011). Furthermore, as large numbers may be culled for welfare reasons 
as a result of movement restrictions within vaccination zones, this should be considered during 
outbreak resource requirement planning (Hadorn, Durr et al. 2013).  
One paper sought to clarify FMD vaccination policy in the USA by presenting several key decision 
makers with an outbreak scenario to establish when and why they would implement emergency FMD 
vaccination (Parent, Miller et al. 2011). Elsewhere, the influence of different stakeholders on control 
policy found that in France a vaccination based strategy was always the preferred national policy 
despite regional differences (Marsot, Rautureau et al. 2014). 
Livestock movements 
The enormous scale of livestock movements is responsible for much of the impact of notifiable disease 
outbreaks. In an attempt to mitigate this, more restrictive routine movement regulations were 
implemented in many countries in the wake of the devastating 2001 outbreak in Northern Europe. 
However, a Dutch study found that in the long term the scale of trading and movements returned to 
pre-outbreak levels despite increased regulation (Brouwer, Bartels et al. 2012). However, following 
past outbreaks in the UK, routine movement standstill regulations have been maintained as part of 
the FMD control policy as a key component of limiting spread of the virus. 
 Thorough policy evaluation following outbreaks is rarely performed in most countries and should 
be encouraged to inform improved decision-making. 
Movement data are crucial inputs for most livestock models. Where they are lacking, the utility of 
models may be limited. In turn, the impact of movement restrictions is a common model output. The 
effectiveness, timeliness and compliance of movement restrictions is typically found to be of 
paramount importance (Buhnerkempe, Tildesley et al. 2014). In addition, effective tracing of livestock 
movements has also been shown to drastically reduce the impact of outbreaks in free countries 
(Hagerman, Ward et al. 2013, Mardones, Zu Donha et al. 2013).  
The need for farmers to both report disease and to undertake legislated control measures is critical 
for outbreak control. In Texas, USA, farmer compliance was likely to be suboptimal in terms of case 
reporting, collecting cattle for examination and observing a movement standstill during an outbreak 
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(Delgado, Norby et al. 2012). Understanding factors underlying non-compliance may aid design of 
more widely-accepted methods, or of appropriate incentives to support the FMDV control effort. 
Preparedness 
Disease outbreaks are often initially detected at abattoirs, highlighting the importance of frequent 
inspections by well-trained inspectors (Hernandez-Jover, Cogger et al. 2011). Unfamiliarity with exotic 
diseases at all levels, including farmers, can also contribute to a lack of preparedness. To help address 
this, EuFMD have run real-time training courses in endemic countries where government 
veterinarians, mostly from free countries, obtain first-hand experience of FMD outbreaks (Gardiner 
2013). These courses equip participants with diagnostic sampling and field epidemiology skills 
necessary for vets in the field during FMD outbreaks. Importantly they expose vets who have often 
never seen a case of FMD to real outbreaks, providing training in clinical diagnosis and biosecurity 1. 
 Awareness and preparedness training should also involve livestock keepers and other relevant 
stakeholders within livestock value chains.  
The potential role of FMD in bioterrorism has been considered by some governments due to the 
relative ease with which highly contagious material can be obtained from outbreaks in endemic 
countries and the severe economic consequences of outbreaks in disease-free countries (Farsang, 
Frentzel et al. 2013). Some governments have used prediction models to estimate resource 
requirements during an outbreak and how availability of manpower influences the impact of an 
outbreak (Garner, Bombarderi et al. 2014). One study suggested that for outbreaks in Australia, 
stamping out would be effective, however, if human resources were limited then a vaccination 
strategy may be preferable to culling alone (Roche, Garner et al. 2014). Others have used expert 
opinion and group consultations to explore some of the logistics of outbreak containment. One study 
concluded that depopulation of a large feedlot would be difficult to complete in a humane and timely 
fashion (McReynolds and Sanderson 2014). 
Many countries have described their contingency plans, sometimes specifying where weaknesses exist 
(Diez and Styles 2013, Ding, Chen et al. 2013). These plans are discussed in detail with stakeholders, 
including government officials, livestock leaders, scientists and figures in the wider industry. Of course 
control of transboundary diseases requires not only within-country cooperation and coordination, but 
                                                          
1 http://www.fao.org/ag/againfo/commissions/eufmd/commissions/eufmd-home/eufmd-in-
action/training/en/ 
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wider international and regional collaboration (Corrales Irrazabal 2012, Sumption, Domenech et al. 
2012). 
Environmental impact 
The environmental and public health impact of the mass usage of disinfectant caused concern in the 
Republic of Korea (South Korea) (Kim, Shim et al. 2013) as did large scale burial of slaughtered pigs 
(Yang, Hong et al. 2012). Welfare concerns during mass culling were also an issue in this outbreak. 
Research updates 
Various institutes have active FMD epidemiology research programmes. The Pirbright Institute has 
continued its work on the field evaluation of FMD vaccination programmes, both against field 
challenge and through post-vaccination immunity. IZSLER, in Italy has also helped endemic countries 
with sero-surveys to measure population immunity and post-vaccination response, and to assess 
disease burden and risk factors. The National Institute of Agricultural Technology (INTA) has examined 
population immunity in Argentina. 
CIRAD (Centre de Coopération Internationale en Recherche Agronomique pour le Développement), 
CODA (Centrum voor Onderzoek in Diergeneeskunde en Agrochemie), Wageningen, Onderstepoort 
Veterinary Institute (OVI) and University of Pretoria, and the University of Glasgow are several of the 
member institutes trying to further understand the role of wildlife in FMD epidemiology, further 
discussed in the wildlife section. Other work by CODA has confirmed the importance of NSP sero-
surveillance for the identification of FMDV transmission in the field. CIRAD has also evaluated the 
efficiency of FMD surveillance in South East Asia, assessing participatory approaches to surveillance 
and control. As well as descriptive studies of FMD epidemiology in Tanzania, working with the 
Tanzanian Veterinary Laboratories Agency, the University of Glasgow has collaborated closely with 
The Pirbright Institute on various quantitative analyses of molecular data and how this can provide 
insights into virus ecology and epidemiology, including how viruses evolve within and between hosts 
and how genetic variation relates to population burden of infection. 
CSIRO-Australian Animal Health Laboratory (AAHL) has helped to develop vaccine control strategies in 
the event of an outbreak in Australia. This work has also attempted to identify the strains that pose 
the biggest threat to the Australian livestock economy. 
35 
 
Mirroring the increasing acceptance of models in policy planning, the Technical University of Denmark 
(DTU) has modelled hypothetical FMD outbreaks in Demark. The University of Minnesota is looking at 
FMD control in swine if an outbreak occurred in the US.  
The World Conservation Society-Animal & Human Health for the Environment and Development 
(WCS–AHEAD) has helped look at value chain approaches to manage FMD and food safety risks in the 
beef production chain in Namibia. Elsewhere they have used modelling approaches to understand the 
epidemiology of SAT (Southern African Territories) serotypes in African buffalo in southern Africa. 
With assistance from the USA, Pakistan research institutes have investigated FMD distribution and the 
role of persistently infected cattle and water buffalo. Descriptive studies are also underway in 
Cameroon and Uganda. In Nigeria descriptive studies have been used as a means of increasing 
diagnostic capacity. 
In the Netherlands, Wageningen University have been particularly active. One study found that 
environmental virus accounts for 1/3 of transmission in housed cattle but the route of infection into 
the host remained unknown. They also found that small ruminants were as susceptible as cattle but 
less infectious. Modelling studies estimated that a 2-5km ring vaccination policy could contain an 
outbreak and confirmed that minimising the duration of an outbreak was a critical aspect of limiting 
economic impact. As part of the EU FMD-DISCONVAC project, managed by CODA, they have been 
involved in the validation of FMD control models, something of huge importance given the increasing 
acceptance and reliance on models to advise policy. 
Plum Island Animal Disease Center (PIADC) has been involved in multiple projects in the US as well as 
Africa and Asia. Some projects are technical, such as the FMD bioportal to assist international sharing 
of information and modelling studies; other projects are field-based, including descriptive 
epidemiological studies and evaluation of the role of carriers in the field. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Although the field of FMD modelling is progressing, validated best practices have not yet been 
established. The extent to which generic spread models can be used in different settings also needs 
to be determined. Greater ground testing of real time decision support tools, including those capable 
of estimating cost-effectiveness of different strategies is also required.  
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Developments are also required in surveillance methods, particularly when confirming disease free 
status in vaccinated populations. 
Clear guidance, knowledge sharing and evidence based policy development are required to assist 
endemic countries to control FMD, particularly those with large smallholder farming sectors. 
As molecular and genetic technologies become cheaper and more powerful, so does their use in 
epidemiology. This progress needs to continue as major breakthroughs could be imminent. The 
incorporation of these tools into practical disease control should be encouraged. 
Basic field epidemiology is under-utilised in the evaluation of control programmes, particularly in 
endemic countries. 
Approaches for identifying high risk strains for incursion and impact in FMD free countries should be 
developed.   
FMD has not been controlled by vaccination alone in the absence of effective biosecurity measures 
and efficient rapid diagnosis. Workable control strategies suitable for developing countries in the early 
stages of FMD control need to be developed and evaluated. 
 
Wildlife and FMD control 
Literature review 
Roles of wildlife species 
A major obstacle to control in certain FMD-endemic regions is the role played by wildlife species in 
maintaining and spreading the disease. Publications between June 2011 and June 2014 have largely 
focused on three different aspects of FMD in wildlife: characterisation of FMD strains, burden of 
infection or susceptibility within specific species and populations; understanding transmission 
dynamics within wildlife populations, and between wild and domestic animals; and defining optimal 
control strategies for those regions where wildlife populations play a significant role in the 
epidemiology of FMD. 
In 2010/2011 FMD-infected wild boar (Sus scrofa) were detected in FMD-free Bulgaria. Infection was 
also detected in domestic livestock. Further investigation revealed clustering of small groups of 
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seropositive animals in both wild boar and deer populations, suggesting that these species have a 
limited capacity to maintain and spread FMDV (Alexandrov, Stefanov et al. 2013). Surveys of wild boar 
in Turkey subsequently determined a sero-prevalence of 20% in animals within endemic regions 
(Khomenko, Alexandrov et al. 2012), although finding a clinically-infected animal was extremely rare. 
A modelling study that considered this information, along with the results of experimental studies of 
FMD infection in wild boar (Breithaupt, Depner et al. 2012), supported the hypothesis that the wild 
boar and deer populations on the Bulgarian-Turkish border were unable to maintain FMD infection in 
the absence of infection in domestic animals, but highlighted the possibility that they could play an 
important role in transmission during future outbreaks under different conditions (Dhollander, 
Belsham et al. 2014). 
 There is a need to monitor populations of susceptible wildlife species, as well as factors 
affecting/likely to predict changes in their numbers/geography, e.g. wild boar populations have grown 
enormously in parts of Europe in recent decades, and we must be responsive to the increased risk 
they pose during potential outbreaks. 
The ability of African buffalo (Syncerus caffer) to harbour a number of pathogens that are transmissible 
to domestic livestock creates a costly and complex problem for both farming and conservation 
communities (Michel and Bengis 2012, Caron, Miguel et al. 2013). Although there is some debate, it 
seems probable that African buffalo are the only wildlife species that play a significant role in the 
maintenance of FMD within the region (Weaver, Domenech et al. 2013). Probang samples from 
African buffalo in Tanzania, Zambia and Mozambique contained FMDV serotypes SAT 1-3, suggestive 
of their maintenance within the buffalo populations (Weaver, Domenech et al. 2013, Kasanga, Dwarka 
et al. 2014). A prospective serological study of cattle grazing adjacent to wildlife in Zimbabwe also 
detected sero-conversion to FMD serotypes carried by buffalo, but in the absence of clinical signs, 
indicating the need for close monitoring as part of effective FMD surveillance in these settings (Jori, 
Caron et al. 2014). Another study in South Africa found that cattle made far more contacts with buffalo 
than with other wildlife species (Brahmbhatt, Fosgate et al. 2012), providing further evidence linking 
the two species in maintaining FMDV infections in the wider ungulate population. 
A review of FMD susceptibility in camelids concluded that whereas Bactrian camels are susceptible to 
FMD, dromedaries are not; furthermore, new world camelids of South America have limited 
susceptibility and a low risk of transmitting the infection (Wernery and Kinne 2012). A serological study 
of Mongolian gazelles (Procapra gutturosa) and livestock on the eastern Steppe of Mongolia also 
concluded that FMD spills over to gazelle populations from outbreaks in domestic livestock, and 
control efforts need to focus on the latter (Bolortsetseg, Enkhtuvshin et al. 2012). 
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The ability of feral pigs (Sus scrofa domesticus) and white-tailed deer (Odocoileus virginianus) to be 
infected and transmit FMD was confirmed in experimental studies (Mohamed, Swafford et al. 2011, 
Moniwa, Embury-Hyatt et al. 2012). The role that deer and feral pigs could play in epidemics in the 
USA was further explored in a modelling study, but our knowledge of FMD transmission in wildlife 
populations is limited, and consequently their role in FMD outbreaks is hard to predict (Ward, Laffan 
et al. 2011). 
Wildlife considerations and disease control 
Traditional strategies for controlling FMD at the interface between wildlife and livestock have had a 
negative impact on wildlife, as well as on some human populations. This is particularly true when 
fencing has been used to segregate wildlife and livestock from FMD control zones. There have been 
calls for more balanced approaches that safeguard wildlife populations and do not disrupt the 
ecosystems upon which many people depend for a livelihood: in order to achieve this, a better 
understanding of FMDV circulation between wild and domestic species is required, as is an 
appreciation of the economic value of wildlife (Ferguson, Cleaveland et al. 2013). See commodity 
based trade in socio-economics and international standards section. 
Research updates 
Much is being done to increase our understanding of the role of wildlife in FMD epidemiology. In 
Europe, interest has centred on wild boar (Sus Scrofa) after outbreaks in Thrace and widespread sero-
positivity detected in Turkey. A study by the European Food Safety Authority (EFSA) concluded that 
FMD would not be maintained by wild boar in Thrace (EFSA Panel on Animal Health and Welfare 
(AHAW) 2012). A modelling study highlighted the limitations of passive surveillance and reliance on 
hunting for surveillance in wildlife when compared to active sample collection (European Food Safety 
Authority 2012).  
In sub-Saharan Africa there have been efforts to further understand and quantify the risk of FMDV 
transmission from African buffalo to domestic species. More importantly, efforts are required to 
define conditions under which FMDV-free beef can be produced in regions where the virus is endemic 
in wildlife, without impacting on wildlife and wildlife tourism. 
For a summary of research updates from contributing institutions, see appended Table 2. 
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Research priorities 
A better understanding of the role of wildlife in FMD maintenance and transmission is required in 
various endemic settings. 
This would provide evidence to inform policy on the role of wildlife in official FMD status. 
 
Socio-economics and international standards 
Literature review 
The benefits of controlling FMD in developed livestock sectors that are able to export livestock and 
their products is so apparent that detailed economic studies have not traditionally been required. The 
benefits of FMD control elsewhere are more controversial and less well understood. In the endemic 
setting and in less developed countries, the case for FMD control must be made by detailed and robust 
economic studies in order to justify funding. This is recognised by the PCP-FMD, which states that such 
studies should be performed during the early stages of a control programme (EuFMD/FAO/OIE 2012). 
Despite this, the field receives little attention and methods for estimating the many complex aspects 
of FMD impact are not established. 
The fourteen identified peer-reviewed publications since June 2011 include a handful of studies using 
field studies to estimate the economic impact of FMD on smallholders in endemic countries, mostly 
in South-East Asia (Shankar, Morzaria et al. 2012, Ferrari, Tasciotti et al. 2013, Nampanya, Khounsy et 
al. 2013, Young, Suon et al. 2013, Jemberu, Mourits et al. 2014). FMD control in endemic countries 
has traditionally been deemed a lesser priority, particularly for countries without the potential to 
benefit from FMD free export markets. These studies found that impact was significant but variable 
from region to region. One study in South-East Asia estimated that smallholder outbreaks resulted in 
a reduction in household income of 4-12% (Shankar, Morzaria et al. 2012), in parts of Laos losses in 
FMD affected households may account for 60% of annual household income (Nampanya, Khounsy et 
al. 2013). In many societies cattle are valued as assets even when not traded for financial gain, but 
rather as a resource that can be “cashed in” at times of need. Thus FMD can have big impact on 
livelihoods even when livestock are not raised in a commercially intensive way. 
One paper looked at the effect of FMD on market prices in the Philippines and found that: pig farm 
and pork wholesale prices dropped 11.8% and 15.7%, respectively; somewhat surprisingly, chicken 
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farm and wholesale prices declined by 21.1% and 14.2%; and that the margins of pig and chicken 
traders were also adversely affected (Abao, Kono et al. 2014).  
Some modelling studies incorporated economic consequences when assessing national effects of FMD 
(Boklund, Halasa et al. 2013, Martinez-Lopez, Ivorra et al. 2014). Although this can be uncertain, 
economics is critical in policy making and must not be neglected by researchers.  
There was one review of the global impact of FMD which estimated that in endemic countries FMD 
causes a global economic impact, due to production losses and vaccination costs alone, of around 
US$6.5 to 21 billion per year (Knight-Jones and Rushton 2013). Two papers looked at theoretical and 
technical issues associated with animal health economics (Hasler, Howe et al. 2011, Gosling, Hart et 
al. 2012). In addition there were several studies on disease prioritisation (Chatikobo, Choga et al. 2013, 
Jibat, Admassu et al. 2013, Onono, Wieland et al. 2013), often finding FMD to be deemed a priority by 
farmers and policy makers in both the developed and developing world, although regional variation 
exists. A handful of additional reports on FMD impact in endemic countries were published in the grey 
literature (Ashenafi 2012, Botswana parliamentary inquiry 2013, Limón, Guitian et al. 2014).  
International standards for trade 
The standards required to trade with official FMD free status are prescribed by the OIE. The waiting 
period required before livestock exports can resume after an outbreak in a free country has been 
eradicated vary depending on whether vaccination was used and the fate of the vaccinated animals, 
i.e. whether they have been removed or not. Some have argued that given, sufficient surveillance, a 3 
month waiting period should apply after vaccination regardless of whether vaccinated animals are 
later culled or not (Barnett, Geale et al. 2013, Geale, Barnett et al. 2013). Of particular importance is 
the ability to prove FMD freedom within a vaccinated population, usually by clinical and passive 
surveillance supplemented with extensive sero-surveillance using imperfect diagnostic tests. Possible 
approaches and problems have been considered (Caporale, Giovannini et al. 2012), however, 
challenges remain. Furthermore, unlike for diagnostic tests, clinical detection of FMD has not been 
evaluated in terms of sensitivity and specificity and this limits the certainty we can have in disease free 
certification (Knight-Jones, Njeumi et al. 2014). 
Commodity-based trade is based on the principle that the FMD-free status of a product can be assured 
without the need for complete FMD freedom within a large geographic zone including wildlife 
(Thomson, Penrith et al. 2013, Thomson, Penrith et al. 2013). The benefit of this approach is that not 
only does it remove the need to enclose and restrict the movements of people, livestock and wildlife, 
it also reduces the impact of FMD outbreaks on distant farmers that would otherwise lose access to 
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export markets though loss of zonal FMD free status, making livelihoods more dependable and trade 
less volatile. Furthermore, by increasing the accessibility of lucrative export markets, more producers 
have a stronger incentive to control FMD. 
Research updates 
Collaborations between the University of Sydney and local partners in South-East Asia have looked at 
FMD impact in Smallholder systems, an area of interest to international donors. This area is being 
reviewed by researchers at The Royal Veterinary College and the International Livestock Research 
Institute (Knight-Jones and Rushton 2014). Although mortality from FMD is low, the continued, and 
widespread, high disease incidence clearly leads to a heavy burden of disease at the population level. 
However, FMD impact in smallholder systems has received relatively little attention and more studies 
are needed. 
Studies at the Friedrich-Loeffler-Institute (FLI) and The Pirbright Institute have also looked at bio-
safety of certain livestock products to begin to understand the FMD risk associated with international 
trade. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Improved understanding of farmer participation in disease reporting and control, including how best 
to use compensation as a tool for disease control. 
Improved understanding of the impact of FMD and FMD control, particularly in endemic countries 
with limited potential to access export markets. 
Real-time use of economic models to guide disease control during outbreaks. 
Options for FMD control and status in wildlife endemic settings, such as commodity based trade, 
require ground testing.  
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Vaccines 
From the 2010 Gap Analysis 
Priority research aims stated were to: 
1. Develop vaccinal needle-free strategies to induce mucosal as well as systemic responses in 
 susceptible species 
2. Develop vaccine formulations effective in neonatal animals with or without maternal 
 immunity 
3. Investigate the safety and efficacy characteristics of novel attenuated FMD vaccine 
 platforms 
4. Understand and overcome the barrier of serotype- and subtype-specific vaccine protection 
5. Design and engineer second-generation immune refocused FMDV antigens 
6. Improve the onset and duration of immunity of current and next generation FMD vaccines 
7. Develop next generation FMD vaccines that prevent FMDV persistence 
8. Invest in the discovery of new adjutants to improve the efficacy and safety of current 
 inactivated FMD vaccines 
9. Develop vaccine formulations and delivery targeting the mucosal immune responses 
Literature review 
The vaccine field is the best represented in terms of number of new publications since 2011, with 
many investigators conducting small scale trials of a range of innovative vaccine approaches. For a 
review of new vaccine technologies see (Rodriguez and Gay 2011). The licensing of the first FMDV 
vaccine for emergency use in the US has revolutionised the landscape, and an increasing appreciation 
of the importance of mucosal and cellular immune responses to successful vaccine strategies is 
filtering through into rational vaccine design studies. Moreover, several exciting developments in the 
arena of needle-free delivery systems have been made, but are yet to be translated to large-scale field 
condition trials. 
Novel/new vaccines 
At the point of writing the 2010 Gap Analysis, a new generation of Human adenovirus 5 (Ad5) derived 
FMD vaccines was under development by PIADC in conjunction with industry partners GenVec. In 
October 2012, the first such vaccine was licensed for use in cattle in the US under outbreak conditions. 
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The licensed vaccine comprises an adjuvanted formulation of replication-deficient human adenovirus 
5 (Ad5) engineered to encode the FMDV structural proteins VP0, VP1 and VP3, alongside the viral 
protease 3C required for their cleavage from the polyprotein. In culture, the structural proteins will 
spontaneously assemble into empty capsids that retain much of the immunogenicity of inactivated 
whole virus. Employing recombinant adenovirus in place of live FMDV offers significant advantages 
for the security and ease of vaccine production, which has enabled the vaccine to be manufactured 
on the US mainland. Encoding only the FMDV proteins required for empty capsid assembly should also 
permit differentiation of infected from vaccinated animals (DIVA) by conventional detection of anti-
NSP antibodies in recovering animals, or with the FMDV 3D ELISA that is being developed in parallel 
with the vaccine. Efficacy studies are reported to show protection from as early as 7 days post-
vaccination in greater than 95% of cattle following a single immunization. 
While the newly-licensed vaccine undoubtedly represents a major leap forward in the field and is well 
suited to meet the needs of an epidemic in the US, its potential benefits in FMD endemic regions may 
be limited as a result of, for example, its storage requirements. However, the empty capsid, or virus-
like particle (VLP), strategy could be exploited in a different way: in place of producing recombinant 
virus with the aim of generating the VLPs in vivo following immunization, empty capsids can be 
synthesized in vitro as a vaccine antigen. Until recently, the problem with this approach was the 
cellular toxicity of FMDV 3C protein, leading to low/variable yields of capsid; we now know that yields 
of serotype O and A capsid from mammalian cells can be markedly improved through limiting the 
expression of 3C relative to P1-2A by a variety of means (Gullberg, Muszynski et al. 2013, Polacek, 
Gullberg et al. 2013). Using a novel construct encoding FMDV A P1-2A, with 3C frame-shifted to reduce 
its activity, researchers from the Pirbright Institute extended these findings into insect cells, where a 
high level of FMDV serotype A empty capsid expression was achieved with minimal toxicity. 
Importantly, the capsids produced were recognised by sera from both infected and vaccinated cattle 
(Porta, Xu et al. 2013). The same group then showed that by incorporating a mutation designed to 
stabilize the capsids during exposure to heat or low pH, they could produce a commercially-viable 
vaccine candidate able to induce strong humoral responses in cattle and sustained protection from 
challenge (Porta, Kotecha et al. 2013). 
 This approach could prove revolutionary for the production of FMDV vaccines in a safe and cost-
effective way. Their efficacy in susceptible species other than cattle remains to be evaluated, and it 
will be necessary to understand their stimulation of non-humoral aspects of the immune response in 
order to fully optimize their design and formulation. 
44 
 
Several other groups have also shown promising results using various VLP strategies: FMDV Asia 1 
capsids produced in E. coli protected cattle and swine from challenge, and stimulated FMDV-specific 
T-cell proliferation and IFN-γ secretion in cattle (Guo, Sun et al. 2013); using mammalian cells grown 
in suspension culture may also prove an easily scalable method of empty capsid production for FMDV 
vaccines (Mignaqui, Ruiz et al. 2013). Furthermore, targeted modifications to the FMDV capsid 
sequence can render vaccine viruses more stable as well as facilitating their adaptation to tissue 
culture, for example, introducing lysine at VP1-110 significantly enhanced cell culture adaptation of 
the virus which has the potential to enable vaccine manufacture of an increased range of strains 
(Berryman, Clark et al. 2013). 
Groups working in Japan have recently begun to explore the possibility of using chimeric plant viruses 
engineered to contain short viral sequences as a safe way to produce vaccines. Li et al showed that a 
9 amino acid sequence from FMDV VP1 could be expressed on the surface of apple latent spherical 
virus and produced in Nicotiana benthamiana plants. The same strategy applied to expressing 
epitopes from zucchini yellow mosaic virus induced specific antibody responses in immunized rabbits 
(Li, Yamagishi et al. 2014), and thus may warrant further attention. 
Alongside novel methods of subunit vaccine production, advances in our understanding of how best 
to design such vaccines also hold promise. A study in mice has highlighted the importance of the 
conformation and valency of the epitopes used: following previous work showing that dendrimeric B 
cell/T cell fusion peptides induced superior B and T cell responses and better protection compared to 
their linear counterparts, this study went on to reveal that fewer copies of the B cell epitope could be 
at least as effective as more copies, and that the inclusion of an optimally oriented T cell epitope was 
important for immunogenicity (Blanco, Cubillos et al. 2013). In target species, we are some way from 
a parallel level of knowledge, but progress is being made, notably towards the definition of predicted 
CD8 T cell epitopes in swine (Liao, Lin et al. 2013), which as seen above may be a valuable addition to 
the vaccine-stimulated anti-FMDV response. 
An interesting approach to vaccine design involves immunising with a recombinant live attenuated 
Peste des petits ruminants virus (PPRV) expressing the VP1 gene from FMDV. In goats this strategy 
successfully stimulated both neutralising antibodies to PPRV and enabled protection from virulent 
FMDV challenge after a single vaccination (Yin, Chen et al. 2014). 
 While unconventional, the potential economic advantages of a dual vaccine are undeniable, and 
this study highlights the power of using the PPRV as an internal live viral adjuvant which may serve to 
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elevate the anti-VP1 response to a protective level in sheep and goats, usually unattainable with 
conventional subunit vaccines. 
Needle-free administration 
A major challenge in vaccine design is the move away from needle-based administration systems. 
Given the importance of inhalation as a route of transmission of FMDV, and the known importance of 
the local mucosal immune response for rapid protection, FMD is in fact a good candidate for an 
effective intra-nasal or even oral vaccine. Researchers working in Korea orally administered 
recombinant FMDV VP1 conjugated to Co1, a peptide mimic of bacterial cell wall components, which 
targets the protein conjugate to M cells of the intestinal Peyer’s patches, the gateway to mucosal 
lymphoid tissue, to enhance its immune-stimulatory capacity. While protection assays were not 
included, an enhanced VP1-specific IgG and IgA response was evident in the mice, both in the mucosa 
and systemically, relative to VP1-alone treatment (Kim, Lee et al. 2013). Similarly, Iranian scientists 
have shown that the inclusion of inactivated FMDV into chitosan nanoparticles for intra-nasal 
application is effective in guinea pig models, particularly in terms of inducing high levels of mucosal 
IgA production (Tajdini, Amini et al. 2014). Further improvements might be made by targeting the 
chitosan nanoparticles to antigen-presenting cells within the mucosa via their mannose receptors: 
guinea pigs intra-nasally immunized with mannosylated chitosan nanoparticles containing a plasmid 
encoding FMDV VP1, mounted strong FMDV-specific IgA responses in the nasal mucosa and exhibited 
60% protection from challenge (compared to 80% from conventional vaccine) (Nanda, Hajam et al. 
2014).  
 Little work has been done on needle-free administration of mucosal-targeted vaccines in natural 
host species of FMDV. While any studies in non-natural target species must be interpreted cautiously, 
the strategies noted above are novel, rational and warrant serious consideration for evaluation and 
optimisation in susceptible livestock species. 
Vaccine adjuvants 
The adjuvant field is appropriately an area of much active research, but it must be borne in mind that 
murine immune systems differ profoundly to those of target species, as does their response to the 
artificially forced FMDV challenge used to evaluate protection. As well as evaluation in target species 
and comparison with commercial vaccine, qualitative aspects of the induced response should be 
studied in order to understand their correlation with the speed, robustness and longevity of protection 
from challenge. Physiologically-relevant adjuvants should be preferred for this reason, as opposed to 
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synthetic/non-specific immune stimulants or those originating from non-viral pathogens, which risk 
sub-optimal polarization of the immune system. 
The adjuvant research field has expanded dramatically in recent years with an increasing appreciation 
that the agents added to vaccines have not only the potential to magnify the immune response to the 
target antigen, but to shape the intricacies of the long-lived response to the immunizing agent. As 
seen above, the quality of the response can be just as important as the quantity when determining 
long-term protection from disease. 
Several studies in mice have tested different adjuvants to FMDV vaccines and reported a level of 
success, though the extent to which this is translatable to natural FMD target species remains to be 
seen. Combining oral adjuvants with conventional FMDV vaccination is potentially attractive, and a 
study in mice fed a plant-derived polysaccharide from Radix Cyathulae officinalis Kuan and also given 
conventional FMDV vaccine, saw significantly higher FMDV-specific antibody titres, increased 
frequency of CD4+ IL-2, IFNγ and IL-4 producing cells, and decreased frequencies of T-regulatory cells 
compared to conventional FMDV vaccine-treated animals (Feng, Du et al. 2013). Similar results have 
been produced by the same group using different antigens in mice (Feng, Du et al. 2014). While no 
challenge data are available, the detailed characterization of the ensuing immune response to the 
vaccine is encouraging on a number of levels, and coupled with the advantages of oral administration 
of a natural product, warrants further investigation in appropriate animal species. 
Using Toll-like Receptor (TLR) ligands as adjuvants to stimulate antigen-presenting cells is a popular 
approach, and there is some evidence that Poly I:C, a mimic of a virus-derived TLR3 ligand, can 
significantly increase cellular and humoral immune responses and reduce inter-individual variation in 
protection in pigs when combined with a multi-epitope subunit FMDV vaccine (Cao, Lu et al. 2013), 
supporting their earlier data in mice (Cao, Lu et al. 2012). TLR9 detects DNA patterns associated with 
microbes, including CpG oligodeoxynucleotides (ODN). ODNs are well-known immunostimulators, but 
a recent study showed the potential advantage of a novel conformation of ODN; the structure of the 
ODN determines the differential activity of the adjuvant on human immune cells, affecting levels of 
cellular internalization, intracellular targeting of the ODN and induction of Type I IFNs. The authors 
also combined nanorings of ODNs with inactivated FMDV vaccine and observed enhanced Th1 
responses in mice (Gungor, Yagci et al. 2014). The nanoring concept is clearly distant from application 
to commercially available FMDV vaccines at this stage, but may prove a useful tool for understanding 
the impact of differential antigen targeting upon ensuing immune responses, and therefore to rational 
design of improved vaccines and adjuvants in the FMD field. 
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Many adjuvants will increase the magnitude of some aspect of the immune response, and may also 
increase the speed of induction, but the polarizing effects on the immune system are often overlooked 
and ill-understood. Using physiologically relevant adjuvants possesses the advantage that the immune 
response that’s enhanced should also be of the “right” type to counter the viral threat. For example, 
the cytokine IL-2 may deserve investigation as an immune-stimulating addition to FMDV vaccines 
(Chen, Zeng et al. 2014), perhaps to increase the speed of onset of adaptive immunity in an outbreak 
situation. Of particular interest, one study assessed the potential of using small synthetic RNAs of the 
FMDV IRES as a novel adjuvant to two inactivated FMDV vaccine formulations in mice, and found that 
VNT were consistently higher in IRES-adjuvanted groups, that the onset of neutralising antibody was 
faster, and mean viraemia was lower following challenge (Borrego, Rodriguez-Pulido et al. 2013). In 
many ways this, or similar, strategies could represent the ultimate in rationally-designed adjuvants. 
Using a highly immune-stimulatory component of the live virus itself, in a non-infectious form, 
accompanied by inactivated FMDV protein shells should not only increase the magnitude of the 
immune response, but will go some way towards ensuring that the vaccine-induced response is a 
closer match to that induced by live virus, and needed for protection against the same threat. 
Combining adjuvants aims to achieve a similar improvement to the tailoring of the response, and 
several publications have shown synergistic effects: both plant-derived adjuvants, in this case 
Rapeseed Oil and Ginseng Saponins (Zhang, Wang et al. 2014), and the synthetic TLR7/8 ligand R848 
and poly I:C combined with traditional aluminium hydroxide-adjuvanted vaccine (Zhou, Li et al. 2014) 
have shown promise. Potential differences in receptor expression amongst immune cells and in the 
fundamental processes of immunity between inbred laboratory mice and outbred cattle, pigs or 
sheep, for example, render it impossible to predict the extent to which such results are translatable 
between species, though the approach is certainly of interest. 
 The adjuvant field is appropriately an area of much active research, but it must be borne in mind 
that murine immune systems differ profoundly to those of target species, as does their response to 
the artificially forced FMDV challenge used to evaluate protection. As well as evaluation in target 
species and comparison with commercial vaccine, qualitative aspects of the induced response should 
be studied in order to understand their correlation with the speed, robustness and longevity of 
protection from challenge. Physiologically-relevant adjuvants should be preferred for this reason, as 
opposed to synthetic/non-specific immune stimulants or those originating from non-viral pathogens, 
which risk sub-optimal polarization of the immune system. 
Differentiation of infected from vaccinated animals (DIVA) 
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An obstacle to the use of vaccines during outbreaks in FMD-free countries is the subsequent inability 
to differentiate infected-recovered animals from vaccinates that also test positively for FMDV-specific 
antibodies. Conventional vaccines have traditionally relied on the absence of antibodies to viral NS 
proteins to enable differentiation of infected from vaccinated animals (DIVA), but this relies on every 
infected animal making the anti-NS response, and zero contamination of the vaccine with NS proteins. 
A marker vaccine with a deletion within FMDV 3A may offer some improvement (Li, Lu et al. 2014). 
However, this strategy similarly relies on 100% response rate of infected animals to the deleted region 
of 3A. The use of attenuated non-transmissible deletion mutants appears equally effective and far less 
risky in terms of accidental release (Uddowla, Hollister et al. 2012), similar to the newly-licensed US 
vaccine, further increasing the attractiveness of such approaches. 
Quality control and vaccine matching 
Methods for assessing the quality of FMD vaccines are well established and internationally accepted 
(European pharmacopoeia 2012, OIE 2015). However, there is always the potential to improve existing 
methods and research is ongoing.  
A recent investigation of locally-produced and imported FMD vaccines available in Pakistan revealed 
alarming differences in quality (Jamal, Shah et al. 2013), clearly illustrating the importance and need 
for effective quality control in the vaccine-manufacturing process. However, advances in vaccine 
technology mean that state-of-the art methods for antigen production, purification and formulation 
may be technically and/or economically out-of-reach for some endemic countries. Scientists working 
at the Pirbright Institute have engineered a recombinant FMDV expressing the influenza 
haemaglutinin protein and a FLAG tag, either of which can be used to cheaply and easy purify virus 
from infected cell cultures (Seago, Jackson et al. 2012). 
 Coupled with appropriate quality control measures, improved methods enabling the rapid and 
effective purification of FMDV for vaccine production purposes could markedly improve control in 
endemic areas in a short time span and their development should be supported.  
 Routine independent evaluation of vaccine batch quality is fundamental to all successful 
vaccination programmes and needs to be promoted.  
The quantity of intact viral capsid present in dose of vaccine is critical for immunity. Novel approaches 
have been developed to improve the measurement of capsid stability, something traditionally difficult 
to assess (Thermoflor assay, PaSTRy: Particle Stability Thermal Release Assay). As well as the 
assessment of vaccine quality, these methods will aid the study of determinants of capsid stability, 
49 
 
highly relevant to vaccine development (Walter, Ren et al. 2012, Seago 2014). Quantification of 
vaccine antigen content using specific Llama antibodies has also shown promise (Perez-Martin 2014). 
An important measure of the quality of a vaccine is the vaccine potency test, which aims to measure 
protective power and ensure between-batch consistency. Traditional potency tests required direct 
challenge of a limited number of animals to measure the protection of a given vaccine or vaccine 
batch, but this approach is time-consuming, expensive, and may not predict protective power in the 
field (Goris, Merkelbach-Peters et al. 2007, Knight-Jones, Edmond et al. 2014). Alternative approaches 
continue to be explored and are used routinely in some regions: modifying the OIE challenge test 
procedures could make it possible to reduce the number of animals used with minimal losses of 
sensitivity or specificity (Reeve, Cox et al. 2011). Attempts to correlate bovine serological responses 
to vaccine protection have potential and are increasingly used for batch quality evaluation, murine 
responses may also be of use (Molin-Capeti, Sepulveda et al. 2013). The newly-licensed Ad5-vectored 
FMD vaccine is, by its nature, highly amenable to in vitro testing for batch potency and inter-batch 
consistency. In parallel with development of the vaccine, researchers at PIADC have defined a panel 
of tests including traditional modified-live vaccine virus infectivity assays, coupled with liquid 
chromatography and several immune-chemical assays, that may have the potential to replace live 
animal potency testing for this vaccine (Brake, McIlhaney et al. 2012). 
Various in vitro methods of estimating cross-protection against heterologous strains have been 
proposed, but a recent study concluded that only the liquid-phase blocking ELISA offered sufficient 
reliability and accuracy to be a serious consideration (Tekleghiorghis, Weerdmeester et al. 2014). That 
said, in vitro methods proved valuable in understanding a lack, or loss, of vaccine mediated protection 
during outbreaks of divergent strains in Ecuador between 2008 and 2011 (Maradei, Perez 
Beascoechea et al. 2011, Maradei, Malirat et al. 2013). Furthermore there are data to suggest that in 
vitro matching using IgG subtypes and avidity tests may perform better than the traditional r1 value 
tests (Lavoria, Di-Giacomo et al. 2012, Brito, Perez et al. 2014); but while genetic sequencing should 
be able to predict antigenic sites, and therefore vaccine matching, a recent study using serotype A 
FMDV concluded that this approach was insufficiently reliable (Ludi, Horton et al. 2014).  
Overall, a widespread move from large animal challenge experiments towards in vivo laboratory 
models or in vitro assays to predict vaccine potency is not imminent, particularly in the case of animals 
less well-studied than cattle, such as buffalo (Madhanmohan, Yuvaraj et al. 2014), or goats and sheep 
(Madhanmohan, Nagendrakumar et al. 2012), where live challenge remains the gold standard. 
However, further careful exploration of possibility of using small animal models, or of reduced 
numbers of large animals (Reeve, Blignaut et al. 2010, Reeve, Cox et al. 2011), and defining the most 
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appropriate surrogate measures for in vitro assay should move us closer toward this goal in the near 
future (Reeve, Blignaut et al. 2010, Reeve, Cox et al. 2011). 
It has become apparent in recent years that while laboratory controlled infections of vaccinated 
animals are well-accepted, they are typically variable, under-powered (Goris, Merkelbach-Peters et al. 
2007) and poorly recapitulate many aspects of field infections. Hence, there has been increasing 
interest in the evaluation of actual protection achieved under field conditions (Knight-Jones, Edmond 
et al. 2014). This is an important, but neglected, area as while different approaches have been 
investigated, further assessment of their strengths and weaknesses is required before a standardized 
approach can be adopted (Muleme, Barigye et al. 2012, Elnekave, Li et al. 2013, Knight-Jones, Bulut et 
al. 2014). Again, the measurement of serological parameters has proven particularly useful when 
comparing the field efficacy of different vaccination schedules, in this case during the FMD outbreak 
in Korea in 2010/2011 (Lee, Lee et al. 2013). 
Research updates 
The vaccine research and development field continues to be well investigated by numerous institutes 
around the world. 
CEVAN (Centro de Virología Animal) of Argentina is exploring the use of novel vaccine strategies 
incorporating replicative and non-replicative vectors in combination with cytokines, viral replicons or 
recombinant bacterial phages to deliver FMDV immunogens. 
Researchers working in China at the LVRI are collaborating with scientists at CODA in Belgium and the 
Pirbright Institute in the UK to understand optimal induction and measurement of mucosal immunity 
against FMDV in cattle. Using nanoparticles to deliver FMDV antigen and cytokine combinations 
showed potential to induce early nasal IgA responses, the magnitude of which was inversely 
associated with disease severity, virus excretion, and onset of clinical symptoms. Alongside, LVRI 
scientists are developing and testing novel peptide epitope vaccines, synthetic peptide vaccines, 
inactivated engineered FMDV vaccines, and a vaccine based on a recombinant baculovirus expressing 
the whole FMDV capsid. In addition, using E. coli to produce FMDV VLP was effective and is being 
further explored as a vaccine production strategy. 
In Belgium, CODA has been coordinating the FMD-DISCONVAC (development, enhancement and 
complementation of animal-sparing, foot-and-mouth disease vaccine-based control strategies for free 
and endemic regions) research program that has been running since 2009. Within the project remit, 
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CODA itself is currently focusing on understanding immune correlates of protection, developing in 
vitro antibody-based assays to measure vaccine purity, and improving methods of quantifying antigen 
payload in manufactured vaccine batches. In addition, a set of studies on correlating immunological 
measures with homologous and heterologous protection from challenge following vaccination have 
yielded important results. A refined method for predicting changes in r-values from sequence changes 
was proposed, which together with the experimental data has the potential to improve vaccine-
matching predictions. Promising vaccine trials have also been conducted: both canine adenovirus- and 
encephalomyocarditis virus- vectored FMDV vaccines have been produced and tested, as well as 
replication defective human adenovirus- (with and without IFNα) and Sendai virus- vectored vaccines 
that have been developed specifically to enhance the mucosal immune response. 
The FLI have also been working towards the FMD-DISCONVAC project, carrying out several cross-
protection studies using conventional monovalent serotype A vaccines. Overall, while challenge virus 
specific VNT titres correlated well with protection, they uncovered evidence that some recent isolates 
from the Middle East cannot be covered by the high potency A vaccines that previously did provide 
sufficiently broad cross-protection. In addition, the FLI is testing the potential of viral vectors 
expressing different combinations of FMDV proteins to be used as novel vaccine candidates, with 
animal challenge experiments planned for the most promising candidates. 
The University of Glasgow is heavily involved in developing strategies to increase the effectiveness of 
vaccination against FMDV, with focus on India. In particular, they aim to: define improved tools for 
vaccine strain selection via reverse genetics and modelling approaches; to determine whether cross-
serotype protective antibodies can be induced, and to characterise them; and to develop new 
approaches to monitor FMDV infections within cattle populations to trace virus circulation and permit 
measurement of vaccine effectiveness. In addition, the possibility of improving FMDV vaccine 
formulation using novel adjuvants developed for use in humans is currently being assessed, with 
emphasis on strengthening the T cell component of immunity to FMDV. Alongside improvements to 
vaccination/monitoring procedures and the vaccine formulation itself, researchers at Glasgow are also 
addressing ways of replacing live animal challenge with in vitro measures of vaccine efficacy. The 
current project aims to develop a framework to better understand the relationship between 
serological assays and live animal challenge results, exploiting modern statistical tools to enable 
accurate prediction of protection based on in vitro immunological parameters. 
A collaborative project between INTA and the Biotechnology Research Institute of the National 
Research Council, Canada aims to develop a panel of VLP-based FMDV vaccines targeting locally-
circulating strains for initial testing in vitro and in a mouse-based in vivo protection model. The most 
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promising candidates will move forward into immunological characterisation and challenge in cattle. 
INTA also has several other projects focusing on development of novel or improved vaccines, including 
extending their study of the use of dendrimeric T and B cell epitope peptides to induce immune 
responses from pigs into cattle, and evaluating safety and efficacy parameters of inactivated FMDV 
formulated with a novel vaccine adjuvant, Providean-AVEC®, developed by INTA scientists with the 
assistance of the National Scientific and Technical Research Council of Argentina. This nanoparticle-
based adjuvant has been rationally designed and targets host antigen-presenting cells with TLR 
ligands; initial studies in mice, cattle, pigs and fish using a range of antigens have indicated superior 
performance to either oil- or aluminium hydroxide- based adjuvants. A second adjuvanting approach 
being trialled is the use of recombinant baculoviruses combined with conventional FMD vaccines. The 
current project aims to characterise the effect of including baculovirus as a means to stimulate both 
innate and adaptive responses in mice, and will define immune response profiles and effect on 
protection against challenge. DNA vaccines are low-cost and safe, but often of insufficient potency for 
use in the field. In a planned study, a DNA vaccine encoding the FMDV polyprotein will be co-
administered to mice with plasmids containing the sequence for immune-stimulatory CD40L and IL-
15, either with or without an additional adjuvant, to understand the potential of this strategy to 
improve immune responses and protection from virulent FMDV challenge. Lastly, while many 
conventional serological assays have been developed for cattle, their performance in other species is 
less well validated. INTA plan to assess the suitability of these assays for use in buffalos and pigs, in 
order to identify the most appropriate high throughput immunological assay to measure anti-FMDV 
immune responses following vaccination or infection of these species. 
At the Indian Veterinary Research Institute (IVRI), ongoing work is focused on the use of a baculovirus 
platform to develop a novel vaccine and accompanying NSP-based diagnostics to enable DIVA. The 
use of the bacterial TLR ligand, flagellin, is also being explored as an adjuvant, as is the inclusion of 
recombinant Hsp60, which functions as a chaperone protein that may improve vaccine antigen 
presentation on host antigen-presenting cells, and therefore increase immunogenicity. Guinea pig 
data appear promising, and trials in cattle are planned. To complement this work, a collaborative 
project between the IVRI, the FMD project directorate in Mukteswar, India, and PIADC is being 
undertaken to develop and test an adenovirus-based vaccine encoding the capsid sequences of Indian 
vaccine strains of FMDV. Preliminary cattle data support the immunogenicity of the vaccines, but 
indicate the need for further dose/schedule optimisation before the initiation of planned challenge 
studies. 
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The National Livestock Resources Research Institute (NaLIRRI) in Uganda is planning a set of studies 
defining important cellular and humoral immune parameters in the response to conventional vaccine 
across a range of relevant species, including cattle, goats, sheep and pigs. In particular they will focus 
on the impact of age and breed in determining the magnitude and quality of response. 
In South Africa, the OVI is involved in a multi-site project with the University of Glasgow, The Pirbright 
Institute and SACIDS (Southern African Centre for Infectious Disease), aiming to develop improved 
indirect and informatics-based methods of vaccine matching with field strains. This interesting 
approach uses mathematical predictions of protective B cell epitopes, based on genetic and structural 
data and in vitro assays, with which to compare vaccine and field viruses and thereby predict the 
extent of shared antigenicity. Associated work has also highlighted qualitative differences between 
assays often used interchangeably to determine antigenic match between field viruses and vaccine 
strains, which is an unresolved issue for effective vaccine strain selection. An approach to overcome 
the impact of viral antigenic drift is also being developed in conjunction with PIADC, which may enable 
molecular “fine tuning” of vaccine strains to improve their protective power in the field. A second 
project aimed at improving current vaccine production strategies is also underway, in collaboration 
with Wellcome Trust Consortium scientists, in Oxford, UK. Through structural modifications to the 
virus, substantial improvements in thermal stability and cell-culture adaptation have been made, 
which may overcome pressing problems in the conventional manufacturing process, particularly for 
SAT serotype FMDV. Planned trials in cattle will assess immunogenicity, efficacy and shelf life of the 
newly-engineered vaccines. 
The Pirbright Institute plan to employ reverse genetics approaches (capsid switching, partial capsid 
switching and site-directed mutagenesis), to understand the relationship between serological cross-
reactivity, capsid amino acid sequence conservation and capsid structure. They will trial the strategy 
of combining heterologous serotype A vaccine strains in an attempt to improve antigenic cover against 
a third heterologous strain, in conjunction with Indian Immunologicals Ltd (IIL) in Hyderabad. 
PIADC is involved in a suite of collaborative and independent research projects aimed at improving 
understanding of the vaccinal immune response, the development of novel vaccines, and approaches 
to overcome the limitations of conventional vaccines/their production. With the University of 
Vermont, Canada, the impact of breed-specific responses to FMDV are being incorporated into a 
strategy to accelerate the development of improved vaccines, and alongside, data are being collected 
on the impact of bovine leucocyte antigen sub-type on responses to the human adenovirus-vectored 
FMD vaccine developed by PIADC. With scientists at Australia’s CSIRO-AAHL, PIADC aims to 
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understand the optimal vaccination protocols for sheep, and to define the appropriate challenge 
conditions with which to test emergency vaccines in this species. 
In a separate development, ARS scientists at the PIADC have engineered a recombinant vaccine seed 
virus (the FMD-LL3B3D platform) to improve safety in case of virus escape from the production facility. 
This virus can replicate in cell culture but is attenuated in cattle and swine; moreover the deletion of 
selected epitopes from the virus should allow the development of companion tests enabling DIVA. 
Importantly, relevant capsid sequences can be substituted into the chimeric virus seed to provide 
immunity against different strains. This engineered vaccine seed is then used to produce inactivated 
vaccine in the conventional way. This new vaccine technology has been transferred to Zoetis and is 
currently under development with the support of ARS scientists.  
 Chimeric vaccines, such as the FMD-LL3B3D, represent another promising avenue for the 
production of improved FMD vaccines. 
The University of Wageningen in the Netherlands is conducting a set of studies that are linking the 
antibody response and protection induced by conventional FMD vaccines with vaccine dose and 
antigen concentration, as well as mode of administration. The sensitivity of response to the 
composition of the vaccine in particular has highlighted the risk of generalising results between 
vaccines from different manufacturers, the impact of which has been under-estimated until now. They 
are also concerned with developing reliable in vitro assays that correlate immune parameters (such as 
serology, measurement of IFN-γ release, capacity of sera to promote FcR-mediated FMDV 
phagocytosis and the plasmacytoid DC IFN-α response) with in vivo protection, as a means to reduce 
reliance on animal experiments. In parallel, investigations are being made into methods to improve 
vaccine production and quality monitoring and thereby increase overall inter-batch confidence and 
industry standardisation. 
IZLER scientists are similarly aiming to improve vaccine production and quality control by the 
development of novel ELISAs for quantification of FMDV 146S or 12S. Moreover, in collaboration with 
CODA in Belgium, they are conducting work to standardise serological testing of field samples between 
different laboratories and to understand the extent and impact of existing variations. 
For a summary of research updates from contributing institutions, see appended Table 2. 
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Research priorities 
The use of FMD virus-like particles as a vaccine has the potential to revolutionise the production of 
effective FMDV vaccines in a safe and cost-effective way. However, their efficacy in species other than 
cattle is incompletely defined, as are their effects on non-humoral aspects of the immune response. 
Several novel adjuvanting or vectoring strategies for various FMD vaccines also show promise but will 
require further testing in target species under physiological challenge conditions. Whilst convenient 
and cheap, the use of murine systems may need to be de-emphasised in light of accumulating data on 
relevant differences between their immune systems and those of natural FMD target species. In 
addition, the importance of qualitative aspects of the response to FMDV infection and vaccination, 
such as the characteristics of non-neutralising antibodies, or the immunoglobulin isotype ratio 
induced, must be recognized, and these parameters should be included during the evaluation of novel 
adjuvants or vaccines. To provide meaningful reference, conventional vaccine should be included 
alongside any novel approach in all studies. 
Improved methods enabling the rapid and effective purification of FMDV for conventional vaccine 
production are under development which, if rolled out widely, could improve control in endemic areas 
within a relatively short time. 
Some studies have begun to indicate possible ways of using needle-free strategies to induce protective 
mucosal responses to FMDV vaccines, but further study of mucosal immunity in target species 
(perhaps requiring the development of additional tools), both in general and in relation to FMD, will 
be required to realise the potential of this strategy. 
Despite much effort, reliable immune correlates of protection remain to be identified. An absence of 
standardised approaches to vaccination and challenge is likely to have contributed to this problem, 
and should be addressed as a matter of urgency, ideally in collaboration with the OIE, for example, to 
ensure widespread uptake of recommendations in future studies. 
Predicting vaccine matching with emerging field strains remains a challenge. 
Control of FMD in endemic regions would be markedly assisted by improving formulation of quality 
controlled vaccines and reagents to extend shelf life and reduce cost, thereby improving availability 
and efficacy. 
Lack of independent evaluation of vaccine quality is a major deficiency that holds back many control 
programmes.  
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Biotherapeutics 
From the 2010 Gap Analysis 
Priority research aims stated were to: 
1. Testing Ad5-IFN distribution and expression in cattle after aerosol exposure 
2. Evaluate the ability of Ad5-type I IFN platform to confer rapid onset of protection (18 hr) 
against several FMD serotypes and subtypes 
Literature review 
Vaccines as a primary line of defence suffer from the unavoidable weakness that the vertebrate 
adaptive immune system needs time, at least 7 days from the first inoculation, in order to mount a 
potentially protective antibody and/or T cell response. In an outbreak situation, this gap may be 
bridged by the application of rapid, short-acting biotherapeutics aiming either to stimulate a non-
specific anti-viral state in the animal, or to specifically inhibit a part of the viral life cycle for sufficient 
time to allow a vaccine to become available, or until the response to the vaccine grows sufficiently 
strong. 
Immune-modulators 
Replication-defective human adenovirus 5 (Ad5) has attracted much interest as a potential vector for 
bovine and porcine interferons to improve early control of FMDV. Earlier data showing protection of 
swine from multiple serotypes of FMDV as early as 1 day post-administration of the Ad5 bearing 
porcine IFN α (Dias, Moraes et al. 2011) have been supported and extended to describe the ability of 
Ad5 encoding Type III IFN to either prevent or substantially protect from FMDV in both pigs (Perez-
Martin, Diaz-San Segundo et al. 2014) and cattle (Perez-Martin, Weiss et al. 2012). The lack of 
protection of cattle by Ad5 encoding bovine Type I IFN is perhaps consistent with the finding that only 
low levels of IFNα are seen in this species during FMDV infection (Windsor, Carr et al. 2011), which 
remains to be fully understood in terms of species-specific mechanisms of immunity. 
Though effective, impractically high doses of the Ad5-vectored interferons are likely to be required for 
their direct applicability to outbreak control in the field. Accordingly, several modifications to the 
approach have been attempted to increase potency; instead of incorporating the sequence for the 
interferon itself into Ad5, encoding a constitutively-active transcription factor targeting type I IFN 
induced high levels of IFNα production in mice, and protection from FMDV challenge as soon as 6 
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hours post-treatment, which lasted for approximately 4 days (Ramirez-Carvajal, Diaz-San Segundo et 
al. 2014). Treatment of pigs with stabilised poly I:C combined with replication-defective adenovirus 
encoding IFNα was also effective in inducing sterile immunity to A serotype FMDV, and at high doses 
the stabilized poly I:C alone could stimulate high levels of Type I IFN production in vivo and protect 
from disease (Dias, Moraes et al. 2012). Data in mice indicate that including IFNγ in tandem with IFNα 
in the recombinant adenoviral vector, and exploiting FMDV 2A to cleave the two cytokines after 
transcription, might be more effective in preventing FMD than either protein singly (Kim, Kim et al. 
2014), which would be easily tested in swine. Taking a different route, exchanging the Ad5 vector for 
Venezuelan equine encephalitis virus empty replicon particles encoding porcine IFNα protects porcine 
cell lines from infection by FMDV, as well as rendering mice resistant to lethal challenge 24 hours post-
administration (Diaz-San Segundo, Dias et al. 2013). 
An alternative interferon-related target is interferon-induced transmembrane protein 3 (IFITM3), 
which is an antiviral effector of the innate immune system that has been recently characterised in 
swine. Inducing expression of sIFITM3 in BHK cells blocked FMDV infection at the point of entry, and 
sub-cutaneous inoculation of suckling mice with a plasmid encoding sIFITM3 was able to protect 
against lethal challenge at 48 hours post-administration (Xu, Qian et al. 2014). Direct treatment with 
small synthetic RNA sequences from the FMDV IRES or 3’ non-coding region of FMDV at the same time 
as pathogen inoculation was also able to protect suckling mice from lethal challenge with Rift Valley 
Fever Virus (Lorenzo, Rodriguez-Pulido et al. 2014), highlighting the potential utility of the strategy 
using either FMDV or unrelated viral sequences, which is yet to be tested as a biotherapeutic in FMDV 
infection  
While the potential benefits of biotherapeutics are clear, their integration into epidemic control 
strategies in the field remains untested. As immune-modulators, they have the potential to both 
positively and negatively impact immune responses to pathogens: to illustrate, there is evidence from 
swine and mice that high levels of type I IFN early in viral infection may be involved in supressing the 
T cell response (Summerfield, Alves et al. 2006, Langellotti, Quattrocchi et al. 2012) and therefore it 
cannot be assumed that the application of IFNα-based biotherapeutics, prior to, or concurrent with a 
conventional vaccine will not adversely impact the response to that vaccine. 
Previous work at PIADC ago that showed that porcine IFN-α enhanced protective immune responses 
to FMDV in pigs vaccinated with a replication-defective adenovirus containing FMDV capsid and 3C 
proteinase coding regions (Ad5-A24) (de Avila Botton, Brum et al. 2006). 
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 The interaction of immune-modulating biotherapeutics with the ensuing proposed vaccine must 
be addressed as a matter of urgency, with particular emphasis on detailed characterisation of both 
qualitative and quantitative effects on the quality and duration of the immune response in key target 
species. 
Anti-viral interventions 
Non-immune-modulating biotherapeutics have been less explored, but may also hold promise. 
Harnessing the host’s own transcriptional silencing mechanisms to prevent FMDV genome replication 
has been attempted with limited success using short-interfering RNAs, but micro-RNAs may hold more 
promise. A plasmid encoding dual miRNAs targeting the IRES region proved able to delay or prevent 
death in suckling mice when co-administered with high doses of FMDV from multiple serotypes. 
(Chang, Dou et al. 2014). 
Moreover, the many and varied roles of FMDV 3Cpro make it an attractive target for pharmacological 
inhibition, and a recent study both designed an improved cell-based assay to test candidate 
compounds and used it to identify AG7088 (Rupintrivir) as a potent 3C inhibitor (van der Linden, 
Ulferts et al. 2014). This is particularly interesting as Rupintrivir was originally developed by Pfizer as 
an aerosolised treatment for the common cold in humans, and therefore may prove amenable to 
further development as an intra-nasal biotherapeutic to impede the early stages of FMDV infection in 
outbreak situations. 
Research updates 
CODA has a program of research targeting discovery of anti-FMDV biotherapeutics with which to 
supplement current outbreak control measures. They have found three different classes of anti-viral 
compounds are active against FMDV in both guinea pigs and immunodeficient mice. One compound 
underwent several rounds of modification and retesting that produced lead compounds active against 
the FMDV protease 2C, and inhibited the early phases of replication of the virus. However, technical 
limitations have precluded further development of these compounds for large-scale use. In contrast, 
high-throughput screening of 65,000 small molecules revealed three compound classes active against 
multiple serotypes of FMDV in vitro that could be easily and cheaply manufactured on large scales. 
Preliminary studies in guinea pigs and mice are ongoing. 
The IVRI are interested in the potential use of small interfering RNA (siRNA) as an antiviral strategy 
applicable to FMDV control. Four siRNA sequences targeting FMDV 3Cpro have been designed and 
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show efficacy in reducing FMDV replication in vitro. Alongside, IVRI plan to exploit the adenoviral 
delivery system to develop and test IFN α and λ based therapeutics for early FMD control. 
INTA are also interested in the possibility of using RNA interference (RNAi)-based antivirals to control 
FMDV, but with a focus on artificial microRNAs, which may offer a safer means of intervention than 
the use of short-hairpin RNAs or small-interfering RNAs which have previously been proven effective 
against FMDV replication in culture. 
Scientists working at PIADC are focusing their biotherapeutics research on immune-modulators, 
particularly those able to induce NK cell activity, such as IL-15. However, as little is known of the 
precise role of NK cells during FMDV infection of cattle or pigs, work will be conducted to characterise 
the function of NK cells in the early stages of infection of these species. New reagents will be generated 
to assist this work, and biotherapeutics will undergo testing both in vitro and in vivo. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
In 2010, the use of adenovirus to vector IFNα (Ad5- IFNα) into hosts and induce short-lived non-specific 
protection from FMDV appeared promising. It now seems that Ad5-IFNα alone is insufficiently potent 
for use in outbreak situations. However, studies combining Ad5-IFNα with an additional immune 
stimulator reveal some potential, as does Ad5 encoding an IFN-stimulating transcription factor in place 
of IFNα. Substituting Type III IFN into the Ad5 vector appears more effective, particularly in cattle, and 
warrants further investigation. 
An area of urgent unmet research need is the potential interaction of immune-modulating 
biotherapeutics with the response to the ensuing proposed vaccine. Before their use in the field, we 
must know how expression of large amounts of these innate immune cytokines affects both 
qualitative and quantitative aspects of the immune response in target species. For example, high levels 
of IFNα can adversely impact the magnitude of T cell responses, which in the case of FMD vaccination, 
could preclude the formation of sufficient immunity to confer protection from disease. 
Non immunological, small molecule inhibitors of FMDV 3Cpro have been identified, but remain to be 
tested in target species in vivo. 
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RNA interference-based strategies are also being explored, though their suitability for upscaling to the 
levels required in outbreak situations has yet to be assessed. More generally, the integration of 
biotherapeutics into existing emergency measures similarly remains to be achieved.  
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Disinfectants 
From the 2010 Gap Analysis 
Priority research aims stated were to develop low cost commercially available disinfectants for use in 
the inactivation of FMDV on contaminated surfaces found in farm settings and other susceptible 
environments. 
Literature review 
Little has been published in this area in recent years, though a single study addressed the 
environmental and public health impacts of the mass usage of disinfectant during outbreaks of FMD 
in South Korea (Kim, Shim et al. 2013). 
Research updates 
PIADC are leading current work in the disinfectant field. They have several ongoing and planned 
projects aiming to develop accepted disinfectant efficacy test methods and to establish the efficacy of 
selected antimicrobial pesticides for inactivating FMDV on a range of surfaces and under various 
conditions. In addition, IZSLER are investigating the kinetics of and conditions for chemical and thermal 
inactivation of FMDV in field and laboratory environments. The Pirbright Institute has an established 
quality-assured disinfectant testing service, and reference to the standards used here may prove 
helpful to the work of PIADC and IZSLER. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Planned and ongoing research would appear likely to meet the 2010 Gap Analysis goals. The potential 
environmental and public health impacts of disinfecting agents, whether novel or established, should 
be evaluated and incorporated into the decision making process on their use. 
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Diagnostics 
From the 2010 Gap Analysis 
Priority research aims stated were to: 
1. Determine the link between molecular serotyping and protective immunity 
2. Support the development of new technologies for pen-side testing 
3. Evaluate and validate commercially available pen-side tests to “fit for purpose” for 
 surveillance, response, and recovery 
4. Proof-of-concept testing of herd immunity test correlated with efficacy of vaccine in the 
 National Veterinary Stockpile 
5. Identify FMDV-specific non-structural protein antigenic determinants for development of 
 DIVA diagnostic tests 
6. Develop serotype-specific rRT-PCR assay(s) 
7. Development of TIGR technology for FMD serotyping/subtyping for rapid vaccine matching 
 and monitoring variation of the virus during an outbreak of FMD 
8. Assess the feasibility of infrared thermography as an FMD screening tool under different 
 environmental field conditions in healthy and diseased animal populations. Assess the 
 potential application of this technology to aid in the identification and sampling of suspected 
 animals for confirmatory diagnostic testing 
9. Investigate the use of artificial intelligence for the development of algorithms to recognize 
 FMD signatures in domestic animal species (cattle, pigs) 
10. Assess the use of air sampling technologies and validate their use for FMDV aerosol 
 detection in open and enclosed spaces 
Literature review 
Diagnostic tests are routinely used to confirm clinical diagnosis when outbreaks are detected; detailed 
analysis of the infecting isolate is important to allow routes of spread to be identified and appropriate 
vaccines to be selected, while serology is used to both establish freedom from infection and to monitor 
the likely level of post-vaccination immunity. The literature since June 2011 describes both novel 
diagnostic tools and refinements to existing methods or their use in various settings. In particular, the 
application of different diagnostic approaches to outbreak scenarios is a key factor, as there is likely 
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to be a sudden need to conduct large numbers of tests on critically short timescales (Paton and King 
2013). 
Antigen detection 
To facilitate strain typing, RT-PCR methods have been developed that can rapidly amplify the capsid-
coding region of the FMDV genome (Le, Lee et al. 2012, Xu, Hurtle et al. 2013); another novel RT-PCR 
used minor groove binder technology for the detection of FMD of all serotypes (McKillen, McMenamy 
et al. 2011). The Pirbright Institute have recently reported the development of serotype specific rRT-
PCR assays for FMDV strains circulating in the Middle East (Reid, Mioulet et al. 2014), which was 
highlighted as a research priority in the 2010 GFRA Gap Analysis. 
 A number of RNA detection assays targeting the FMDV genome have been developed using reverse 
transcription loop-mediated isothermal amplification (RT-LAMP), with some detecting single 
serotypes and others multiple (Chen, Zhang et al. 2011, Madhanmohan, Nagendrakumar et al. 2013, 
Yamazaki, Mioulet et al. 2013, Ding, Zhou et al. 2014, Kasanga, Yamazaki et al. 2014). RT-LAMP was 
faster, simpler, more cost-effective and at least as sensitive and specific as RT-PCR. Furthermore, it 
has been successfully used in a portable platform to allow rapid diagnosis in the field (Abd El Wahed, 
El-Deeb et al. 2013). 
The development of RT-LAMP represents an important breakthrough that will enable increased 
usage and access to molecular diagnostics. 
A number of studies describe the generation of monoclonal or polyclonal antibodies for use in FMD 
immuno-assays (Lin, Li et al. 2011, Chen, Peng et al. 2012, Cho, Jo et al. 2012). One paper described 
FMDV antigen detection using a novel direct ELISA that outperformed the conventional indirect ELISA 
(Morioka, Fukai et al. 2014). Superior serotype specificity was also obtained in a sandwich ELISA using 
recombinant integrin αvβ6 as a capture ligand and serotype-specific monoclonal antibodies as 
detecting reagents (Ferris, Grazioli et al. 2011). Another study developed a recombinant  single chain 
variable fragment as an alternative to immunoglobulins and applied it as a detection agent in an ELISA  
(Sridevi, Shukra et al. 2014). 
Antibody detection 
Conventional tests for antibodies recognizing FMDV structural proteins, which are raised in abundance 
after vaccination or infection, use detection antigens derived from live virus which requires specialized 
bio-safety level 3 facilities to produce safely. The use of recombinant technology as an alternative 
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source of test antigens showed promise in several studies (Ko, Lee et al. 2012, Basagoudanavar, 
Hosamani et al. 2013, Wong, Sieo et al. 2013). One study supported the use of the solid phase 
competition ELISA for FMDV structural protein antibody detection (Li, Swabey et al. 2012). Several 
publications described the development of in-house tests for the detection of viral NSP-specific 
antibodies, the basis of most DIVA assays (Jaworski, Compaired et al. 2011, Gao, Zhang et al. 2012, 
Sharma, Mohapatra et al. 2012, Srisombundit, Tungthumniyom et al. 2013, Biswal, Jena et al. 2014, 
Mohapatra, Mohapatra et al. 2014), including a Luminex assay (Chen, Lee et al. 2013). But regardless 
of the test used, relying on the detection of anti-NSP antibodies to detect infection in vaccinated 
populations is imperfect, as vaccinated cattle may occasionally sero-convert, particularly after 
repeated vaccination and persistently infected cattle with localised rather than systemic infection may 
not develop a detectable NSP antibody. Thus certifying freedom in vaccinated populations based on 
NSP sero-surveillance comes with an element of uncertainty. 
Sequencing 
Next generation sequencing technologies have emerged that allow sequencing of not only the 
predominant sequence but also minority variants present within a single sample. This technology has 
been used to explore within-host virus evolution and selection in a way not previously possible 
(Wright, Morelli et al. 2011, King, Madi et al. 2012), substantially advancing our knowledge of FMDV 
population dynamics within the animal. 
 Molecular and genetic technologies play a central role in our ever expanding knowledge of virus 
ecology and transmission. 
Pen-side tests  
Besides RT-LAMP, mentioned above, developments in pen-side diagnostics include the evaluation of 
a portable real-time PCR amplification platform (Madi, Hamilton et al. 2012). Another study described 
a high-speed quantitative PCR assay which provided results in <30mins (Wernike, Beer et al. 2013), 
which could be a substantial advantage in the urgency of an outbreak situation. Variations of the 
lateral flow device were produced, including one for the detection of vesicular stomatitis (Lin, Shao et 
al. 2011, Ferris, Clavijo et al. 2012, Yang, Goolia et al. 2013). The use of thermal imaging to assess hoof 
temperature for the early detection of FMD was found to be of limited accuracy (Gloster, Ebert et al. 
2011). 
 Progress has been made in the field of rapid diagnostics, but further advances would be beneficial, 
particularly for methods that allow strain typing. 
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Screening  
A multiplex RT-PCR assay, combined with microarray typing, was used to detect and type all serotypes 
of FMDV and vesicular stomatitis virus in one test protocol (Lung, Fisher et al. 2011). Another multiplex 
PCR assay was able to screen samples for six different porcine pathogens that can present with similar 
clinical signs [including FMD] (Wernike, Hoffmann et al. 2013). 
Sampling 
The use of cotton ropes as a means of obtaining oral fluid samples from pigs was found to have 
reasonable sensitivity (Vosloo, Morris et al. 2013). Similar results were found for rope-in-a-bait as of 
humane way of getting saliva samples from wild boar (Mouchantat, Haas et al. 2014). These 
approaches could be employed to address both feasibility and welfare considerations in regular 
sampling protocols, particularly those involving wildlife. An evaluation of oral swabs versus probang 
sampling found that early viraemia could be detected by both sampling methods in pigs and cattle, 
though persistent infection in FMDV carrier cattle could only be detected using probang samples 
(Stenfeldt, Lohse et al. 2013). Furthermore tonsil swabbing seems to be high effective at isolating virus 
in persistently infected African buffalo (Juleff, unpublished). 
Broader issues 
A clear global picture of the distributions and movements of FMD strains within and between regions 
and countries is lacking. This is due to limited diagnostic capacity and sampling in many endemic 
countries (Namatovu, Wekesa et al. 2013). Cost and complexity present a barrier for the wider use of 
many of the diagnostic techniques mentioned above in developing countries: although there is no 
immediate solution to this problem, pen-side devices have proved useful, RT-LAMP promises to make 
molecular diagnostics simpler and more economical, and there is the prospect that sequencing 
technologies will also likely become more affordable in the future (King, Madi et al. 2012). In FMD-
free countries, early detection of infection is critical and further developments in pen-side tests and 
pre-clinical diagnostics are needed (Paton and King 2013). 
Research updates 
The Pirbright Institute is active in several areas of FMD diagnostic development, many mentioned in 
the above literature review (pen-side PCR, RT-LAMP, next generation sequencing, etc…). In 
collaboration with IZSLER, researchers are working on the development of new monoclonal antibody 
based assays for use in commercial tests. Cost, complexity and biosafety requirements of current tests 
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(antibody and antigen) present a barrier to some countries wishing to perform more FMD diagnostics. 
LVRI in China have a similar diagnostic research interest to The Pirbright Institute, and have developed 
two rapid pen-side tests in the form of a NSP immunochromatographic strip and a Dot-plot kit. 
CODA is also working on ELISA tests for laboratories with limited facilities. In addition, within the FMD-
DISCONVAC project, they have performed validation studies on the IgA and NSP ELISAs as DIVA tests 
and worked on Luminex assays. Like other laboratories they are active in twinning programmes to 
assist laboratories in endemic countries. 
In Argentina, both INTA and CEVAN have done research to improve the use of serology in estimation 
of vaccine protection and immunity, as well as for detection of infection. When mass vaccination is 
used but disease is not present, field evaluation of vaccine protection has to rely on immune correlates 
and not natural challenge. 
In Australia, CSIRO-AAHL has worked on diagnostic capacity in readiness of an FMD incursion. In New 
Zealand, AHL-NZ (Animal Health Laboratory – New Zealand) have performed evaluation studies for 
FMD diagnostics in red deer, which are farmed in large numbers and could play an important role 
should an outbreak occur. 
The University of Glasgow’s work includes the use as milk for NSP tests, PCR and virus sequencing to 
assess population burden of infection. In addition they are interested in assessment of vaccine 
effectiveness in the field and the development of diagnostics in East Africa. FLI have looked into non-
invasive sampling methods, such as baited swab sampling of wild boar and air sampling for pre-clinical 
detection in cattle. They have also worked on various aspects aiming to optimise FMD diagnostics, 
including virus inactivation by nucleic acid extraction buffers. 
The IVRI has looked at the use of a baculovirus expression system to produce the 3ABC protein for use 
in NSP tests without the need for live virus. Wageningen have also looked at NSP tests, assessing 
alternatives to the current commercial tests and studying the timing of NSP antibody responses after 
infection or vaccination in cattle and small ruminants. 
Although initial findings at The Pirbright Institute indicated that the use of thermography for early 
FMD detection may not be promising, further evaluation of the technology continues at other sites, 
including PIADC. Plum Island have also developed a multiplex RT-LAMP that can simultaneously test 
and screen for FMD and Vesicular Stomatitis. In addition they are trying to produce inexpensive 
diagnostic kits for sub-Saharan Africa.  
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For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Continued development of molecular and genetic technologies combined with novel analytical 
techniques is vital, and will in turn benefit many different areas of FMD research.  
Pen-side tests facilitate rapid outbreak detection, which is crucial for minimising the impact of an 
outbreak. Pen-side tests also allow FMD diagnostics where well-equipped laboratories are not easily 
accessible. Although progress has been made in the development of pen-side tests, ongoing research 
is required. In addition, the development of simple and affordable diagnostics, particularly for SAT 
viruses, for use in under-resourced laboratories should be considered a priority. 
Although NSP serology is widely used, it has limitations and improved DIVA tests are urgently required. 
The same is true for vaccine matching assays. Relevant to this is the need to better understand the 
link between molecular characteristics of viruses and cross-protective immunity. Similarly, approaches 
and methodologies for assessing post-vaccination population immunity need to be strengthened, 
standardised and their use widely promoted.  
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Understanding the Virus 
Pathogenesis 
From the 2010 Gap Analysis 
Priority research aims stated were to: 
1. Identify determinants of viral virulence for different serotypes of FMDV in cattle, sheep, and 
 swine 
2. Investigate virus-host interactions at the primary sites of infection in ruminants and their 
 role in determining infection 
3. Determine the early events in FMDV pathogenesis in swine and small ruminants (i.e., 
 primary site of replication, mechanisms of spread) 
Literature review 
Early events and their relation to virulence 
In part, our relative lack of understanding of the events occurring during and immediately following 
the host’s initial exposure to the virus reflects the ongoing need for reliable and reproducible methods 
to simulate natural infection under laboratory conditions. In pigs, two simulated-natural inoculation 
systems were recently developed and tested: intra-oropharyngeal inoculation gave consistent and 
synchronous infections and was preferred over intra-nasopharyngeal administration, which was more 
variable. The same study also highlighted the likely importance of the oropharyngeal tonsils in early 
infection of swine (Stenfeldt, Pacheco et al. 2014). In cattle, administering FMDV-A24 either into the 
tongue epithelium or by aerosol, confirmed data from O serotype viruses that initial replication occurs 
in the nasopharynx, followed by expansion in the lung and systemic viraemia, as well as identifying a 
local Type I and III IFN response at the primary sites of infection. Comparing an attenuated mutant of 
the same strain revealed that virulence determinants at the point of infection were: virus-intrinsic 
factors, host defence mechanisms, and route of exposure (Arzt, Pacheco et al. 2014). 
 Widespread adoption of more physiologically relevant routes of infection for laboratory studies 
appears feasible and desirable to produce data readily translatable to field situations. 
On the cellular scale, it has been known for some time that FMDV tissue tropism cannot be fully 
accounted for by receptor expression alone. Whole genome gene expression profiling now suggests 
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that a combination of receptor (αVβ6 integrin) expression and availability, the capacity of the tissue 
to clear infected cells, and the extent of the type I IFN response locally are the key influencers of tissue 
tropism and the pathogenesis of the viral lesions (Zhu, Arzt et al. 2013). Understanding the tropism of 
FMDV for the heart muscle is particularly pressing, as myocardial infection is the most commonly 
identified cause of death in animals with FMD. New data from pigs infected with chimeric FMDV found 
that alterations to the capsid proteins VP1, VP2 and VP3, had the potential to markedly increase the 
proportion of infected animals dying from myocardial infection (Lohse, Jackson et al. 2012). A 
comparative analysis of fatal FMDV-associated myocardial inflammation in two pigs indicated that 
viral strain differences may also play a role in determining the precise pathology of the condition, but 
that regardless of strain, an abundant NK cell infiltrate was present within the heart muscle (Stenfeldt, 
Pacheco et al. 2014). 
 Moving forward, it would be of interest to determine which features of the strains are associated 
with increased fatality, perhaps focusing initially on capsid proteins, as well as investigating the 
properties of the NK cells infiltrating the heart, and whether they are part of the problem or the 
solution. 
Persistent infection 
Full understanding of the carrier state is a pre-requisite for rational development of vaccines able to 
induce sterile immunity and for planning safe and effective means to trade with endemic countries. 
The presence of FMDV in the germinal centres of carrier ruminants was described for the first time in 
2012 by Juleff et al, working at the Pirbright Institute. Unexpectedly, this virus is also detectable in 
animals defined as non-carriers according to traditional methods (Juleff et al., 2012). Moreover, recent 
evidence indicates a similar phenomenon may occur in pigs (Stenfeldt, Pacheco et al. 2014), which is 
surprising as swine are considered non-carrier species. 
 These findings revolutionise our appreciation of FMDV persistence, but it remains to be seen 
whether their primary importance is as a depot of live virus leading to replication and the emergence 
of the classical “carrier state” or rather as a protective immunological resource with which to maintain 
high antibody titres for prolonged periods. 
A useful tool for understanding persistence at the cellular level has been developed by researchers at 
the University of Wuhan in China. They established a persistently infected cell line and found that the 
molecular basis of persistence was based on selection for modifications to the cellular genome that 
enables resistance to the lytic effects of FMDV (Zhang, Li et al. 2013)  
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 While in vivo persistence is unlikely to be mediated by the same mechanisms, this study offers a 
novel perspective on the problem and could be used as a starting point for investigations of cellular 
factors involved in pathogenesis and as a way to understand how to block FMDV lysis of target cells 
and therefore prevent spread of infection within the animal. 
Research updates 
Persistence 
In an EuFMD-funded project, researchers at the National Agency for Food, Environmental and 
Occupational Health Safety (ANSES) in France plan to characterise both FMDV and host cell 
determinants of persistence on the cellular level, focusing on host transcriptional modifications that 
can overcome FMDV-mediated lysis. It will be interesting to compare the outcomes of this study with 
those already published (Zhang, Li et al. 2013) and to understand to what extent the findings are cell 
type/virus strain specific. 
Transmission 
The Friedrich-Loeffler-Institute has generated important data during laboratory infections of wild 
boar, showing that the disease is clinically mild in this species but follows a similar time course to that 
in domestic pigs; no viral shedding was detected past 9 days post-exposure though viral RNA was 
detected in some tissues at day 27. 
CODA in Belgium has several ongoing/completed studies addressing FMDV transmission. They have 
confirmed that infected Asian buffalo are able to transmit the virus to both naïve buffalo and naïve 
cattle, but that this transmission could be minimized by appropriate vaccination. Also considering 
wildlife, while published data show the capacity for transmission from wild boar, it seems that their 
actual contribution (as for gazelle) is highly variable in outbreak situations. Similarly, it appears that 
the contribution of environmental contamination of the virus is considerable in some situations, 
highlighting the need for development of effective disinfectant protocols in the field. 
The OVI, in South Africa, is involved in a consortium (funded by Oregon state university and the 
Pirbright institute) research project to understand how FMDV is maintained and transmitted within 
the African buffalo. Central to the project is the detailed study of a captive herd of buffalo over 3 years, 
which will include monitoring of FMDV population dynamics, antigenic variation, transmission 
patterns, and the interaction of these factors with secondary influences (co-infection with common 
respiratory pathogens and/or seasonal malnutrition). 
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Researchers from the Pirbright Institute plan to conduct controlled transmission studies to provide 
accurate data that will inform next-generation modelling. By infecting cattle they will define the 
relative importance of different sources of virus emission, identify dominant routes of virus transfer 
between infected and naïve animals, and establish how the virus is most frequently taken up prior to 
infection. 
PIADC, in collaboration with The National Veterinary Research and Quarantine Service, Korea, is 
studying the pathogenicity of Korean FMDV isolates, A/ROK/2010 and O/ROK/2010 in pigs and cattle 
with the specific aims of defining the time course of the disease and transmission windows, and to 
produce a set of reference data and materials for further characterisation. Working with the National 
Agricultural Research Center (NARC) of Pakistan, studies are also underway to define the role of 
persistently infected cattle and riverine buffalo in the persistence and transmission of FMDV. 
Groups working in the Netherlands at the Wageningen University have highlighted the potential 
importance of environmental contamination during FMDV transmission between cattle, finding that 
if the virus persists environmentally for a day or more, it can account for around 30% of transmission, 
which had been previously under-estimated. Virus in the saliva of infected cattle can not only transmit 
to other cattle, but studies also showed that other small ruminants may be similarly susceptible, 
though precisely how the virus is transmitted is a topic of further investigation. The broader scope of 
work also includes improved understanding of FMDV transmission between vaccinated and non-
vaccinated/recently vaccinated sheep, cattle and buffalo as well as quantification of viral load in 
different excretions and secretions from these animals. The aim is to develop a comprehensive 
understanding of the transmission pathways between animals of the same or different species under 
conditions of differing immunity and/or in the field. In parallel, the data generated will be incorporated 
into improved transmission models. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Our understanding of FMDV persistence has been revolutionised by finding that retention of virus in 
the lymph node appears to be more the exception than the rule, even in species not thought capable 
of retaining live virus, such as swine. What remains to be seen is whether this phenomenon is primarily 
to the advantage of host or pathogen. 
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Understanding early events during infection has been hampered historically by widespread use of 
non-physiological routes of challenge. Data now show that widespread adoption of more relevant 
routes of infection for laboratory studies is both feasible and desirable. Standardisation and universal 
acceptance of this approach would be beneficial. 
Beyond expression of integrins, evidence of other determinants of susceptibility at the tissue and 
cellular levels have gained interest in recent years and should be pursued. 
Factors underpinning genetic resistance and age-related susceptibility to FMDV infection warrant 
investigation. 
The factors determining the extent of the role of wildlife species in field conditions during outbreaks 
should be defined with the support of laboratory controlled infections to enable full understanding of 
the disease in non-agricultural species. 
It will be interesting to see to what extent the molecular virulence determinants identified in vitro are 
applicable in target species, and in particular, whether the same determinants are equally important 
for different species. 
 
Immunology 
From the 2010 Gap Analysis 
Priority research aims stated were to: 
1. Study mucosal responses to acute and persistent infections in cattle 
2. Establish the immune mechanisms underlying protection to FMDV during the time-course of 
infection 
3. Study neonatal immune responses to infection and vaccination and the influence of maternal 
immunity in protection and vaccine efficacy 
4. Support research on the immunological mechanisms of cross protection in susceptible species 
5. Determine the role of cellular innate immune responses in FMDV infection of cattle and swine 
6. Develop methods to activate cells of the innate response to anti-viral activity (NK cells, T cells, 
and DCs) 
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7. Contract the development of antibodies to surface markers of critical immune bovine and 
porcine cell types as well as specific for bovine IFNα and β as well as porcine IFNα 
8. Contract the development of antibodies to surface markers of critical immune bovine and 
porcine cell types 
9. Support basic research to understand the Type I interferon locus in cattle and swine and how 
the protein products of these genes affect innate and adaptive immune responses 
10. Determine the differential expression of the IFNα genes in bovine and porcine 
11. Develop technologies for analysing the adaptive immune response to infection and 
vaccination 
12. Determine correlates between cellular immune responses and vaccine efficacy 
Literature review 
Role of B cells 
Illustrating the importance of basic knowledge in FMDV target species, only recently have we 
discovered that the bovine immune system generates antibody diversity in a fundamentally different 
way than other species (Wang, Ekiert et al. 2013), thus bovine antibodies may be able to bind epitopes 
in a way that cannot be modelled using conventional parameters or in rodents. This knowledge could 
have profound implications for the way we consider designing vaccines targeting antibody responses, 
and might be one reason that vaccines can under-perform in cattle when developed in mice. 
 Functional implications of new knowledge on bovine antibody diversity should be elucidated in 
vivo. As part of the broader issue of small animal models, caution should be used when considering 
the applicability of antibody responses generated in rodents to likely outcomes in cattle. 
Several studies have also advanced knowledge of the FMDV-specific antibody response. Recently, 
Pega et al described the kinetics of the early B cell response to aerosol infection, showing that FMDV-
specific antibody secreting cells were present in the lymphoid tissue of the respiratory tract and spleen 
from 4 days post-infection (Pega, Bucafusco et al. 2013). The authors provide evidence to show that 
IgM is abundant early, both locally and systemically, and is responsible for viral clearance independent 
of T cell help. A study using porcine cells has also highlighted the potential importance of non-
neutralising opsonic antibodies that facilitate uptake of bound FMDV by dendritic cells (DC), which are 
potent immune modulators. Summerfield’s group provide evidence that opsonizing antibodies can 
increase plasmacytoid DC-mediated release of antiviral Type I IFNs in response to both homologous 
and heterologous serotypes (Lannes, Python et al. 2012). An earlier study in cattle also showed 
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significant increases in FMDV-specific recall responses in vitro using DC incubated with immune-
complexed UV-inactivated virus (Robinson, Windsor et al. 2011). 
 Virus-neutralizing titre can no longer be considered the sole readout of the value of the antibody 
response to FMDV; there is sufficient data to warrant a thorough investigation of the role of immune 
complexes in vivo in target species during infection and vaccination, and how they might be exploited 
to improve immunity. 
Role of T cells 
The dominance of T cell-independent antibody responses during early FMDV infection is well 
established, though the question remains: are T cell-dependent antibody responses simply not 
stimulated to the same extent, or are they actively inhibited? In mice, there is evidence that early Type 
I IFN production is responsible for diminished proliferation of T cells during infection (Langellotti, 
Quattrocchi et al. 2012). In the same model, chemically-inactivated virus also induced a regulatory T 
cell response. Recent data in cattle have confirmed the likely importance of this observation: Guzman 
et al provided the first conclusive data that bovine gamma-delta T cells are the regulatory equivalent 
of murine and human Foxp3-positive T regs, and also demonstrated the ability of these cells to 
significantly impede FMDV specific CD4 and CD8 T cell proliferation in vitro (Guzman, Hope et al. 2014). 
These findings may explain earlier in vivo observations, where partial depletion of gamma-delta T cells 
shortened the period of viraemia during FMDV infection of cattle (Juleff, Windsor et al. 2009). T 
regulatory cells have now also been defined and characterised in swine (Kaser, Gerner et al. 2011), 
though their functional significance for FMDV infection and vaccination has yet to be investigated. 
 The potential importance of regulatory gamma-delta T cells in the response to vaccination of cattle 
has been underestimated until now, and remains unknown in the case of other target species. Their 
impact on the magnitude of the T cell response to FMDV infection and vaccination should be 
investigated, with a view to minimizing their activation through rational vaccine design. 
A second perspective on the relative weakness of the anti-FMDV T cell response comes from studies 
on their interactions with dendritic cells (DC), which license T cell activation and proliferation. FMDV 
appears to deplete splenic DC in mice (Langellotti, Quattrocchi et al. 2012), while bovine DC are 
effectively killed by live FMDV immune complexes in vitro (Robinson, Windsor et al. 2011). This could 
represent an immune evasion strategy, as the immune complexes formed by FMDV and host 
antibodies early in the response have the potential to destroy any DC attempting to take up the 
complexes and use the digested viral proteins to stimulate FMDV-specific T cells. Such a mechanism 
is consistent with in vivo observations in cattle, where there is little or no induction of the FMDV-
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specific T cell response, while responses to other antigens are unaffected by infection (Windsor, Carr 
et al. 2011). 
It also seems that different mechanisms of T cell suppression may predominate in different species. 
High levels of interferon alpha were linked with early T cell inhibition during FMD in mice (Langellotti, 
Quattrocchi et al. 2012), and a similar mechanism may operate in swine, at least during classical swine 
fever virus infection (Summerfield, Alves et al. 2006). In contrast, in cattle, only low levels of Type I 
IFNs are detected (Windsor, Carr et al. 2011), again consistent with the lack of immunosuppression 
that is evident in other species. 
At least for vaccination, the importance of CD4-expressing T cells is now clear: depleting CD4 T cells 
from cattle significantly reduced virus-neutralising antibody titres and delayed antibody class 
switching (Carr, Lefevre et al. 2013). 
 These data emphasize the importance of T cell responses to optimize vaccine-induced immunity, 
which has been overshadowed by the traditional focus on neutralizing antibodies alone. 
Role of CD8 T cells 
Successful responses against many viruses rely on CD8 T cells, but their role in FMDV immunity 
remains obscure. Infecting swine with FMDV A24 has now been shown to induce specific CD8 
responses, and moreover, a vaccine able to induce FMDV-specific CD8 T cells, critically, in the absence 
of marked antibody responses to the virus, diminished clinical signs and lowered viraemia (Patch, 
Kenney et al. 2013). Several CD8 T cell epitopes have also been identified within the structural proteins 
of FMDV A24 (Pedersen, Harndahl et al. 2013), though whether the responses detected in swine are 
in fact targeted towards these epitopes remains to be seen. While the role of CD8 T cells in cattle 
appears to be minor, the novel approach adopted by Plum Island researchers has yet to be tested in 
other species and may prove uniquely well-suited to answering the question in a way that other 
studies have been unable to. 
 FMDV specific CD8 T cells may be able to reduce the severity and duration of disease, making their 
stimulation a potentially useful adjunct to traditional vaccine strategies. Their role in species other 
than swine may warrant re-examination using new approaches. 
Neonatal immunity to FMDV vaccines 
The neonatal immune system is to some extent immature or perhaps even actively tolerogenic, as a 
result of in utero programming, and this can prove problematic for effective vaccination of young 
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animals. Moreover, the influence of maternally-derived antibodies delivered through colostrum upon 
subsequent immunization is far from clear. Effective protection of this vulnerable population group 
will require thorough knowledge of both these aspects of early life immunity. 
Comparing groups of vaccinated calves with either high or low levels of anti-FMDV antibodies from 
colostrum revealed that abundant maternal antibody may prevent the development of the anti-FMDV 
IgM response, and could interfere with the production of virus-neutralising antibodies. These effects 
could not be overcome by a booster dose of the vaccine; however, the presence of maternal 
antibodies showed some benefit in terms of longevity of the overall anti-FMDV response measured 
by liquid-phase blocking ELISA (Bucafusco, Di Giacomo et al. 2014). The authors highlighted the 
somewhat contradictory findings when considering the data from blocking ELISA versus 
measurements of virus-neutralising titre, and proposed that VNT data might be the more useful in a 
young bovine population. They did not address the neonatal T cell response to vaccination. 
In agreement with these findings, two week old calves without maternal antibodies to FMDV exhibited 
poor humoral responses to the same vaccine that was given to their mothers during pregnancy 
(Dekker, Eble et al. 2014). Interestingly, using an intra-typic heterologous vaccine, calves carrying 
maternal antibodies were able to mount a limited response, leading the authors to propose this as a 
strategy in emergency vaccination protocols in regions that were already employing prophylactic 
vaccines. 
One study did detect induction of high levels of virus-neutralising antibodies in calves with maternal 
antibodies against FMDV, but only using oil- and not aluminium hydroxide- based adjuvants (Patil, 
Sajjanar et al. 2014). While the overall findings are perhaps inconsistent with those of other groups, 
this work does highlight the unaddressed issue of potential differences in efficacy of various adjuvants 
in young animals. 
From outside the field, an intriguing study found that a Human Adenovirus 5-vectored swine influenza 
vaccine was able to overcome interference by maternal antibodies (Wesley and Lager 2006). It will 
therefore be particularly interesting to discover whether the same phenomenon occurs in calves 
vaccinated with the newly-licensed adenoviral FMDV vaccine (see Vaccines). 
 The neonatal immune system of FMDV target species remains far less well characterised than their 
adult counterparts. Neonatal calves seem able to mount responses to commercially-available FMDV 
vaccines, but only in the absence of high levels of maternal antibody, and perhaps only with the “right” 
adjuvant. Further study of neonatal immunity, with particular reference to the T cell compartment, in 
conjunction with side-by-side comparisons of responses to different adjuvants is required. 
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Correlates of protection following vaccination 
In line with the emerging importance of the T cell response to both FMDV infection and vaccination, 
new approaches to predicting protection following immunization are beginning to incorporate 
markers of T cell immunity. For example, combining VNT data with measurements of the levels of IFNγ 
produced by CD4-expressing T cells in whole blood restimulation assays, allowed correlations to be 
seen that were associated with clinical protection following vaccination (Oh, Fleming et al. 2012). 
Interestingly, the extent of the IFNγ response to the two vaccines tested was not dose dependent, and 
did not always reflect the VNT of the animal. 
 This raises the question of which other host-intrinsic factors are involved in determining the 
magnitude of the IFNγ-producing T cell response to vaccination, and how the response might be 
augmented by rational improvements to vaccines. 
Predicting cross-protection between vaccine strains and field isolates is a second important objective. 
Traditionally the likelihood of cross-protection has been estimated by virus neutralization test (VNT), 
liquid phase blocking ELISA and complement fixation assay, but these techniques are labour intensive 
and can be sub-optimally accurate. A recent study assessed the suitability of high-throughput avidity 
and IgG subtype ELISAs to predict cross protection in cattle from serum samples. In cattle immunized 
against FMDV A24 Cruzeiro and challenged with A/Arg/01, protection against the heterologous strain 
was associated with higher avidity antibodies to A/Arg/01. Some animals had low or undetectable 
VNT, yet were protected upon challenge, and this phenomenon was linked to a higher IgG1/IgG2 ratio 
than non-protected animals (Lavoria, Di-Giacomo et al. 2012). 
 Combining VNT and measurements of antibody avidity with immunoglobulin class ratios may well 
improve the accuracy of current vaccine-matching approaches. Moreover, understanding how to 
achieve optimal IgG ratios and increase immunoglobulin avidity could improve vaccine design, 
particularly where cross-protection is a priority.  
The challenges of identifying correlates of protection following vaccination often reflect the more 
fundamental lack of knowledge of the events immediately following the administration of the vaccine, 
long before the emergence of measurable adaptive immune parameters such as neutralising titre. In 
the case of adenovirus-based FMDV vaccines, some progress has been made by the development of 
recombinant adenovirus 5 (rAd5) carrying either a luciferase- or GFP- encoding gene in place of FMDV 
sequences. Inoculation of the traceable rAd5-luciferase particles into cattle revealed the association 
of transgene products with antigen-presenting cells within the inflammatory infiltrate, and from 6 
hours post-inoculation, within the inter-follicular areas of the draining lymph node (Montiel, Smoliga 
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et al. 2013). Experiments using rAD5-GFP revealed that the addition of an oil-based adjuvant increased 
the frequency of expression of the fluorescent protein within lymph migratory DC; in a separate 
experiment, the addition of the same adjuvant resulted in increased frequencies of FMDV-specific 
IFNγ- and TNFα- secreting memory T cells compared to vaccination with rAD5-FMDV alone (Cubillos-
Zapata, Guzman et al. 2011). Taken together these studies illustrate the potential of recent advances 
in our ability to dissect the interaction of vaccine components with antigen-presenting cells and the 
impact such interactions can have on ensuing immunity. 
 Such innovative reagents will prove useful in identifying the key immune cells involved early in the 
induction of the immune response to vectored vaccines, and provide a rational basis on which to 
compare the efficacy of different strategies during this critical initial phase of the vaccine response. 
Research updates 
Researchers at DTU in Denmark have undertaken a package of work to both identify the FMDV 
structural protein peptides that can be bound by class I swine leukocyte antigen alleles, in 
collaboration with PIADC, and to define the epitopes capable of enhancing the anti-structural protein 
response. 
INTA are collaborating with PIADC to understand the development and the protective role of the 
memory B-cell response in lymphoid tissues and nodes of the bovine respiratory tract following 
parenteral administration of FMD vaccine. While the vaccine is known to induce both systemic and 
mucosal immune responses, the underlying mechanisms are unknown, and as improved local 
respiratory tract immunity holds potential to increase protection, this understanding could prove 
valuable in informing improved vaccine/adjuvant design in the future. In parallel, INTA and PIADC are 
also developing techniques to improve our ability to study the induction of adaptive immunity in the 
mucosa following aerosol infection. They aim to establish the time course of parallel induction of 
mucosal and systemic immunity, and to understand the importance of distinct antibody isotypes for 
local in vivo neutralisation of FMDV in cattle. Alongside, technical expertise transferred from the 
Pirbright Institute has enabled INTA scientists to embark on a comparison of the molecular responses 
induced in murine DC and bovine afferent lymph DC by exposure to either live or inactivated FMDV. 
This will contribute substantially to our appreciation of the very earliest steps of initiation of immunity 
to FMDV by vaccination or infection, and the comparative nature may shed light on the extent to 
which we can hope to accurately model bovine immunity at the cellular level in the murine setting. 
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INTA scientists are also investigating non-classical correlates of protection against heterologous 
challenge. In combination with traditional VNT/ELISA, researchers plan to characterise the specific 
serological responses of cattle to vaccination in terms of antibody avidity and isotype profiles, as well 
as cellular immune parameters. This will then be compared to the results of heterologous challenge 
in an attempt to identify the factors most relevant for protection. 
Directly addressing the need for improved knowledge of the factors impacting neonatal responses to 
FMD vaccines, INTA are also planning to define the immune responses of calves in both the presence 
and absence of colostral immunity. As well as valuable information on the composition and kinetics of 
colostral-derived immunity in calves, this study will, for the first time, interrogate the effects on 
cellular immunity in calves and should generate much needed data in this under-studied area. 
PIADC are leading several research projects that will substantially enhance our understanding of FMDV 
immunity: with INTA, they plan to focus on identifying the genetic basis of response levels of FMDV 
infection and vaccination and to what extent these responses are heritable, and in a separate 
collaboration, to exploit in vitro models of FMDV-specific antibody production to determine the 
companion cell types likely to be important in vivo. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
New knowledge on the bovine immunoglobulin response requires interpretation for its relevance to 
FMDV infection and vaccination in natural FMDV target species. 
The importance of non-neutralizing antibodies in the response to FMDV has become apparent, 
particularly in terms of interactions of antibody-bound virus with immune cells. We now need to 
define the roles of these immune complexes in vivo in target species to enable their exploitation. 
Regulatory gamma-delta T cells now appear to play a significant role in the response to vaccination of 
cattle. Similar experiments should be undertaken in other target species to understand the impact of 
this cell type to FMD vaccination in broader terms, particularly in light of new data highlighting the 
importance of T cell responses to optimize vaccine-induced immunity. Similarly, CD8 T cell stimulation 
may also be a desirable outcome of vaccination, but its potential remains unexplored outside of swine. 
The neonatal immune systems of FMDV target species remain far less well characterised than their 
adult counterparts. Further study of neonatal immunity, with particular reference to the T cell 
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compartment, in conjunction with characterisation of FMDV vaccine and adjuvant responses is 
required. 
Qualitative hallmarks of effective adaptive immunity to FMD vaccines and infection are being 
uncovered. Understanding how to use this knowledge in a more comprehensive approach to vaccine 
matching may prove invaluable. Alongside, further study to determine how to achieve optimal IgG 
class ratios and increase immunoglobulin avidity should inform improved vaccine design, particularly 
where cross-protection is a priority. 
Mucosal immune responses remain relatively under-studied in target species. Robust techniques 
should be developed and applied to understand how mucosal and systemic immunity combine to 
provide effective protection following vaccination or during infection. 
 
Molecular Biology 
Literature review 
Defining the molecular features of FMDV has direct applications for how we understand, and 
therefore overcome, infection with the virus, as well as identifying molecular targets that may be 
amenable to therapeutic inhibition in order to prevent viral replication, characterising the effects of 
the virus upon host cells allows us to appreciate its immune evasive strategies. 
 
Cell entry 
At the stage of cell entry, the main new finding is the requirement for phosphatidylinositol 4,5 
bisphosphate (PIP2) within the plasma membrane for integrin-dependent FMDV entry (Vazquez-
Calvo, Sobrino et al. 2012). This is particularly interesting as PIP2 has since been linked to regulation 
of the autophagosome/lysosome system (Rong, Liu et al. 2012), which has emerged as an important 
component of FMDV infection on the cellular level. FMDV induces the formation of autophagosomes 
to facilitate cell entry (Berryman, Brooks et al. 2012), and FMDV 2C protein has been shown to interact 
with Beclin1, a host protein that regulates the autophagy pathway, perhaps as a means of preventing 
lysosomal fusion (Gladue, O'Donnell et al. 2012). 
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As well as the importance of autophagosomes for cell entry, FMDV also requires cellular membranes 
for genome replication. It now seems that these membranes originate from the early secretory 
pathway, specifically the pre-Golgi compartment (Midgley, Moffat et al. 2013), which may link with 
the observation that FMDV 3C(pro) can cause fragmentation of the Golgi associated with a loss of 
microtubule organization (Zhou, Mogensen et al. 2013). These disruptions to vesicular trafficking and 
the secretory pathway are particularly relevant when it comes to the production and release of 
cytokines from infected cells, and the transport of immune-stimulatory MHC/antigen complexes to 
the cell surface. Rearrangements to the internal membrane system of infected cells thus appear to 
serve the dual purposes of facilitating replication and avoiding immune stimulation. 
Immune evasion 
In addition, FMDV has evolved several specific mechanisms to evade the host type I IFN response. 
While earlier work identified roles for FMDV L(pro) and 3C(pro) (Wang, Fang et al. 2012) in inhibiting 
the production of type I IFN, new data show that 3C(pro) can also impede signalling downstream of 
the type I IFN receptor, specifically the nuclear translocation of STAT1 and STAT2 (Du, Bi et al. 2014). 
These molecules have hundreds of potential transcriptional targets, including many anti-viral effectors 
and immune-stimulatory genes. Alongside, studies in tumour cell lines have identified potentially 
relevant alterations to cell signalling induced by FMDV VP1 binding to target cells, including down-
regulation of COX-2/PGE2 and IKK/NF-κB signalling, both of which are important immune pathways 
(Ho, Hung et al. 2014). 
 Taken together these studies highlight the varied and powerful ways in which FMDV manipulates 
the host immune system to permit its replication and spread, and validate the development of 
biotherapeutics to counteract such effects during the critical early days of infection risk in the 
outbreak scenario. 
Molecular virulence determinants 
Alongside host determinants of the virulence of FMDV infections (see (Arzt, Pacheco et al. 2014), 
under Pathogenesis), molecular features of the virus can have profound impacts on the virulence of 
the strain. Attenuation has been linked with both low- and high- fidelity variants of the viral RNA-
dependent RNA polymerase, the latter of which may act by limiting the potential for adaptive quasi-
species emergence (Xie, Wang et al. 2014, Zeng, Wang et al. 2014). In addition, an elegant series of in 
vitro experiments tracked the differential virulence of two A serotype field strains isolated during the 
Argentine outbreaks of 2000/1 to differences in the structure of the internal ribosome entry site (IRES) 
of the viral genome (Garcia-Nunez, Gismondi et al. 2014). Interestingly, the interaction between the 
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IRES and viral 3' untranslated region (UTR) was the key determinant of the level of FMDV replication, 
adding a second level of regulation to the system. 
The roles of FMDV non-structural protein 3A in virulence now appear to be multiple and varied: 
optimal FMDV 3A dimerization has been linked to viral infectivity, at least in vitro (Gonzalez-Magaldi, 
Postigo et al. 2012), while the interaction of 3A with the host protein DCTN3, likely involved in 
intracellular organelle transport, seems to be a potent virulence determinant in both primary bovine 
cell cultures and in cattle (Gladue, O'Donnell et al. 2014). Moreover, while deleting amino acids 87-
106 of the FMDV non-structural protein 3A did not affect virulence in swine, in cattle these mutations 
resulted in limited replication in the pharyngeal area after aerosol infection but no systemic spread 
(Pacheco, Gladue et al. 2013). 
 Thus FMDV 3A warrants further investigation as a determinant of both virulence and host tropism. 
The functional effects of the described mutations should be characterised in order to understand the 
basis of their effects on in vivo virulence. 
Molecular effects of infection 
Our knowledge of the impacts of FMDV infection upon target cells has been advanced by two notable 
studies. As well as direct repression of gene transcription, FMDV infection can alter host cell gene 
expression via modulation of cellular micro-RNAs (miRNAs). In the PK-15 porcine kidney cell line, 
FMDV Asia 1 induced differential expression of 172 known, and 72 novel, miRNAs after 6 hours, 
compared to non-infected cells. Pathway annotation revealed that the miRNAs were abundant in cell 
death and immune response pathways (Zhang, Liu et al. 2014). In addition, another group working in 
China employed high-throughput quantitative proteomics to analyse the global changes in protein 
expression in FMDV-infected IBRS-2 cells. After 6 hours of infection, 77 cellular proteins were 
significantly up-regulated, and 50 were significantly down-regulated, relative to non-infected cells. 
Ingenuity pathway analysis highlighted the abundance of regulated proteins involved in various 
biological pathways including cell movement, intercellular signalling, lipid metabolism and protein 
synthesis (Ye, Yan et al. 2013). 
 These studies represent an exciting new era in the application of precise, quantitative, high-
throughput molecular techniques to the study of FMDV. This unbiased approach holds great promise 
in terms of understanding the molecular pathogenesis of FMDV infection and identifying new 
therapeutic targets for intervention. Future study should focus on the development of improved 
controls for infection (or the use of purified virus), and movement away from cell lines. Early time 
points of infection would be revealing, as would the use of primary immune cells as targets. The extent 
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to which changes observed are driven by the cellular response to virus versus actively induced by 
replication could be addressed by the use of purified inactivated virus, while questions regarding 
cross-species differences in susceptibility could also be addressed at this level. 
Understanding capsid stability 
As seen in the Vaccines section, major advances have been made using FMDV capsids engineered to 
have increased resistance to low pH. This has required some understanding of the molecular 
requirements of acid-resistance: two separate studies on mutants of Type Asia1 or Type C FMDV with 
increased resistance to low pH allowed the identification of parallel single amino acid substitutions at 
VP1 N17D and VP2 H145Y (the residue required for VP0 cleavage) that were key for the acid-resistant 
phenotype (Vazquez-Calvo, Caridi et al. 2014, Wang, Song et al. 2014). Type O FMDV required only 
the VP1 N17D substitution to achieve acid-resistance, which substantially increased its 
immunogenicity under acidic conditions and highlighted the potential of this alteration to improve 
vaccine production (Liang, Yang et al. 2014). 
Research updates 
Following the collaborative project between PIADC (USA), the CBMSO (Spain) and INTA (Argentina) 
that identified the structure of the internal ribosome entry site (IRES) of the viral genome as a 
molecular virulence determinant (Garcia-Nunez, Gismondi et al. 2014), preliminary work has also 
uncovered evidence of a potential virulence determinant from two strains of the virulent subtype that 
is evident in murine infection but not reflected in differences in replication rate in cell culture. 
Sequence comparison has now identified 6 amino acid changes across viral proteins VP2, VP1 and 2C 
as well as 26 synonymous changes throughout the viral genome that are being evaluated for their 
impact on lethality of FMDV in adult mice. 
DTU are conducting a program of research aimed at improving molecular knowledge of the virus, in 
particular they are aiming to understand: the requirements for capsid precursor processing and capsid 
assembly to assist vaccine development, and how to produce self-tagged virus particles through 
modification of a 3C protease cleavage site. 
In a collaborative effort between PIADC and IZSLER, FMDV replication is being analysed from the 
perspective of the host cell. Aiming to identify the host proteins that play critical roles in the process 
of virus replication and to characterize their cellular location, interaction kinetics, and role in the viral 
life cycle, this project may offer new insights and possible points for intervention during infection. 
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Further refinements to our knowledge of FMDV’s interaction with the type I IFN system are being 
sought through research at the FLI, where in vitro assays aim to identify viral and host protein 
interaction partners and to understand their significance within the host cell signalling pathways. 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
The multiple and varied ways that FMDV manipulates the host immune system are becoming evident 
from molecular studies which should serve to both validate and direct design of novel biotherapeutics. 
Substantial data indicate that FMDV 3A warrants further investigation as a determinant of both 
virulence and host tropism, but an emphasis on experimentation in natural host species is required 
moving forwards. 
Exploitation of precise, quantitative, high-throughput molecular techniques to study FMDV offer great 
promise for advances in understanding of pathogenesis at the cellular level. Their future application 
to primary cells or more physiologically-relevant cell lines, combined with careful experimental design, 
will be required for this promise to be realised. 
Considering recent advances in our molecular understanding of FMDV’s interactions with the host IFN 
response, we now need to establish to what extent we can link molecular findings with whole 
organism responses to natural infection. As a starting point, some experiments carried out in 
immortalised cell lines should be repeated in cell lines and/or primary cells from relevant target tissues 
of natural host species. 
New Research Tools and Approaches 
Literature review 
Cell lines are appropriate for preliminary investigation of the molecular events of infection, and in 
particular may be effective screens for potential biotherapeutics aimed at rendering target cells 
resistant to FMDV. There is some evidence that porcine tonsil cells may be applicable for the 
evaluation of oral, low-dose IFN-α treatments (Razzuoli, Villa et al. 2014), and would seem a 
physiologically relevant choice for testing other agents administered either orally or by aerosol. 
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Facilitating improved study of FMDV, new antibodies recognising the NS protein 3AB (Lin, Shao et al. 
2012), and VP1 of type A and type O VP1 (Cho, Jo et al. 2012) have recently been characterised. 
Research updates 
INTA are leading developments in reducing the need for large animal challenge during vaccine potency 
testing through refining trials in mice. The current project aims to measure the correlation between 
vaccine-induced antibody titres in cattle and mice, and the extent to which isotype ratios and avidity 
indices are similar in the two species. 
Our understanding of the immune response to both infection and vaccination against FMDV is 
hampered by an incomplete knowledge of the immune system of natural target species, which is in 
turn compounded by a limited number of reagents with which to study them. PIADC are improving 
reagent availability both directly through the development of new monoclonal antibodies for bovine 
cytokines and immune cell markers, and indirectly, by importing, testing, and making-available 
monoclonal antibodies for bovine immune cell surface proteins previously produced at the 
International Livestock Research Institute (ILRI) in Kenya. Reagents available for immunological study 
of veterinary species can be identified at http://www.immunologicaltoolbox.co.uk and 
http://www.umass.edu/vetimm/ 
For a summary of research updates from contributing institutions, see appended Table 2. 
Research priorities 
Large animal experimentation for FMDV is necessary, but expensive, and suffers from multiple 
practical limitations. Appropriate in vitro and small animal models of the disease have the potential to 
advance knowledge and reduce the number of large animals needed, but the challenge of developing 
and validating the “right” model remains. In parallel, reagent/method development to enable in-depth 
study of the immune systems of target species, particularly the mucosal compartment, would facilitate 
advances in FMDV pathogenesis and vaccine science. 
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Conclusions 
FMD control is constrained by the tools available. Progress accelerates with scientific breakthroughs 
and stagnates in the face of unsolved problems. Progress in disease control can take several forms: 
• Achieving control where previously not possible or allowing a better level of control. 
• Achieving the same level of control but in a more efficient way (time, cost). 
• Allowing increased certainty in disease/infection status, which facilitates control and allows 
access to FMD free markets, thereby increasing incentives to control FMD. 
• Providing increased understanding of a disease, which can improve our ability to describe and 
predict events, or may eventually result in tools for control not anticipated at the time of 
discovery. 
Historically our ability to control FMD has depended on the ability to coordinate control through 
effective veterinary services with control facilitated by the development of imperfect but sufficiently 
effective vaccines, which have changed relatively little in the last half-century. More recently our 
ability to select an effective control strategy has been enhanced by the development of mathematical 
models. Improved diagnostics enable us to detect infected animals in vaccinated populations with 
greater confidence, allowing for less draconian standards for international trade and reduced 
dependency on culling based strategies. Further refinements are required in these areas. 
Currently available tools for FMD control have enabled eradication in much of the developed world, 
however, in many developing countries FMD remains uncontrolled, and with three-quarters of world’s 
livestock living in endemic regions this represents a vast unmet need. In these settings the biosecurity 
measures that have been fundamental to successful FMD control in the developed world can seldom 
be implemented effectively. Improved vaccines, with longer-lasting protection against a wider range 
of strains and lower production costs could therefore be the single most important development to 
allow FMD control where previously not possible. Although this is not imminent, encouraging progress 
has been made with several novel vaccine candidates addressing key weaknesses of the current 
inactivated vaccines. While new discoveries are crucial, uptake and implementation of existing 
methods and technologies is often lacking, and the same compliance frameworks will be crucial for 
the success of any novel strategies that emerge. Lessons learnt about how to control FMD with existing 
quality assured vaccines should be shared and clearer guidance provided to those struggling to control 
the disease despite significant efforts. 
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Another area of huge potential is genetic and molecular research. More powerful tools and analyses 
are promising to increase our understanding of various aspects of FMDV evolution, ecology and 
epidemiology. This in turn will benefit a range of areas, from basic virology, to vaccine and diagnostic 
development. Furthermore improved genetic technologies have the potential to reveal information 
crucial for control, such as transmission chains, vaccine match, and level of virus circulation.  
FMD control has been prioritised by many governments around the world. Increasingly, research is 
being conducted outside the traditional bastions of the established FMD institutes in Europe, North 
and South America, with notable work being done in China and India, and increasing research capacity 
within Africa. Experiences in South America and Europe have shown that through decades of sustained 
investment in FMD research and control, eradication is achievable - even in regions where FMD is 
rampant and control seemingly impossible. Although global control seems far off, progress is being 
made and there is cause for optimism. 
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Appendices 
Contributing Institutions & Financial Support 
Abbreviation Institution Country 
AHL-NZ Animal Health Laboratory New Zealand 
ANSES  Agence nationale de sécurité sanitaire de l’alimentation, de 
l’environnement et du travail (National Agency for Food, Environmental 
and Occupational Health Safety) 
France 
BVI Botswana Vaccine Institute Botswana 
CEVAN Centro de Virología Animal (Center of Animal Virology) Argentina 
CIRAD Centre de Coopération Internationale en Recherche Agronomique pour 
le Développement (French Agricultural Research Centre for International 
Development) 
France - 
International 
CODA Centrum voor Onderzoek in Diergeneeskunde en Agrochemie 
(Veterinary and Agrochemical Research Center) 
Belgium 
CSIRO Commonwealth Scientific and Industrial Research Organisation Australia 
DTU Danmarks Tekniske Universitet (Technical University of Denmark) Denmark 
EUFMD The European Commission for the control of Foot-and-Mouth disease Italy 
FLI Friedrich-Loeffler-Institute Germany 
INTA Instituto Nacional de Technologia Agropecuaria (National Institute of 
Agricultural Technology) 
Argentina 
IVI Institute of Virology and Immunology Switzerland 
IVRI Indian Veterinary Research Institute India 
IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia 
Romagna (Lombardy and Emilia Romagna Experimental Zootechnic 
Institute) 
Italy 
LANAVET Laboratoire National Veterinaire (National Veterinary Laboratory) Cameroon 
LVRI Lanzhou Veterinary Research Institute of the Chinese Academy of 
Agricultural Sciences (CAAS) 
China 
NADDEC National Animal Disease Diagnostics and Epidemiology Centre Uganda 
NaLIRRI National Livestock Resources Research Institute Uganda 
NARC National Agricultural Research Center Pakistan 
NCAD National Centers for Animal Disease Canada 
NIAB Nuclear Institute for Agriculture and Biology Pakistan 
NIBGE National Institute for Biotechnology and Genetic Engineering Pakistan 
NVL National Veterinary Laboratory Pakistan 
NVRI National Veterinary Research Institute Nigeria 
 Onderspoort Veterinary faculty, University of Pretoria, South Africa South Africa 
OVI Ondespoort Veterinary Institute South Africa 
ARS Agricultural Research Service, USDA, PIADC USA 
APHIS Animal and Plant Inspection Service, USDA, PIADC USA 
DHS Department of Homeland Security, PIADC USA 
 Pirbright Institute UK 
 University of Glasgow UK 
 University of Minnesota USA 
Wageningen Central Veterinary Institute (CVI) University of Wageningen Netherlands 
VLA Veterinary Laboratory Agency Tanzania 
WCS-AHEAD Wildlife Conservation Society - Animal & Human Health for the 
Environment And Development 
USA – 
International 
 Zoetis International 
 
This report was produced with funding from EuFMD, FAO.  
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Summary of Research Activities at GFRA and EuFMD Member Institutes 
Table 2: Summary of reported recent, ongoing, or planned FMD research activities at responding GFRA and EuFMD institutes. Instead of listing as a separate category, 
activities relating the wildlife have been highlighted in red. 
Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
AHL-NZ, 
New Zealand 
-Evaluate diagnostic 
tests in red deer 
         
ANSES, France 
   -Cellular models of persistent infection    -Sequencing West African 
& Pakistan 
viruses 
  
BVI, 
Botswana 
       -Sequencing and 
phylogenetics 
of FMD in 
cattle & 
buffalo 
  
CEVAN,  
Argentina 
-Serological tools  for 
detection, population 
immunity and vaccine 
evaluation 
 
-Alternative vaccine 
quality and potency 
tests 
-Typing and 
matching using 
serology, molecular 
and antigenic data 
 -Characterise protein-protein interactions during 
transcriptions and 
replication 
 Vaccines -Vector vaccines (replicative and 
non-replicative +/- cytokines 
-Vaccines using viral replicons,  
bacterial phages with specific 
epitopes & identify novel 
immunogens 
-Rapid 
detection and 
typing   
CIRAD, 
France 
  Epidemiology 
-FMD ecology & control at the wildlife-livestock 
interface in Southern Africa  
-SE Asia-surveillance evaluation &participatory 
surveillance 
      
CODA, 
Belgium 
-Simplified ELISA tests 
-IgA & NSP ELISA 
validation 
-Luminex assay 
-Twinning project  in 
Nigeria 
-In vitro potency 
test 
-Vaccine NSP 
purity test 
-Measure of 
vaccine antigen 
payload 
-Wild boar & gazelle 
involvement in 
outbreaks 
-NSP surveillance 
-Modelling vaccine 
strategies 
-Evaluation of 
simulation models 
-Transmission between 
sheep & cattle 
-Transmission from 
environmental 
contamination 
-Vaccination and 
transmission from Asian 
water buffalo to cattle 
-Onset & duration of 
immunity 
-New DIVA vaccines 
-Heterologous 
protection 
-Vector vaccines 
-Antivirals 
proof of 
concept 
-Cost-
effectiveness 
of antivirals 
-Predicting 
heterologous 
protection   
114 
 
Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
CSIRO, 
Australia 
-Outbreak preparedness 
including diagnostic 
capabilities, strategies 
and reagents 
-Potency testing of 
vaccine bank strains -Identify strains with high risk of 
incursion and 
consequences 
-Develop vaccine 
control strategy 
  -Develop sequencing for 
tracing and 
vaccine selection 
   -Capacity building 
in 
endemic 
countries 
to reduce 
incursion 
risk 
DTU, 
Denmark 
-Develop serotype-
specific RT-qPCR assays -Role of leader protease in blocking 
host cell protein 
synthesis and 
infection 
-Modelling 
outbreaks in free 
countries 
(Denmark) 
 -Identify epitopes that enhance immune 
response 
Vaccines 
-Capsid processing & assembly 
-Analysis of endemic country strains & transmission 
between species including wildlife 
-Next generation sequencing & reverse genetics to 
assess diversity, adaptation & pathogenicity 
  
FLI, 
Germany 
-Baited swab sampling in 
wild boar 
-Inactivation of FMDV by 
nucleic acid extraction 
buffers & optimised 
diagnostics 
-Non-invasive preclinical 
sampling (air sampling?) 
-Heterologous 
potency tests for 
serotype A viruses 
with vaccine bank 
strains, data used 
for improved 
potency prediction 
 -Challenge 
study in 
wild boar 
-How do FMD viral 
factors interfere with 
the IFN-I response? 
-Viral vectors 
expressing 
different FMDV 
proteins as 
vaccine 
candidates 
  -FMD 
cannot 
survive in 
properly 
processed 
sausage 
casings 
-Defining 
minimum 
bio-risk 
manage
ment 
standard
s for 
laborator
ies 
working 
with 
FMDV” 
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Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
INTA, 
Argentina 
-New SAT2 ELISA to 
assess vaccine potency & 
coverage 
-Mice for vaccine 
potency testing 
-Using old & novel 
assays, antibody 
avidity, isotype 
profiles & IFNγ to 
predict 
heterologous 
protection  
-Measuring Ab 
vaccine response in 
buffaloes & pigs 
 
-Population immunity studies & 
identification of immunity gaps 
-Elucidating 
the viral 
determinan
ts of 
differential 
pathogenici
ty of 2 A 
strains, 
considering 
molecular, 
structural 
characterist
ics and 
pathology 
-Development and 
protective role of 
memory B-cells in 
lymphoid tissues and 
nodes+ mucosal Ab 
immunity  of 
respiratory tract 
-Vaccine response in 
pigs assessed by LPB-
ELISA, indirect and 
avidity ELISA, isotype 
ELISA and also cell-
mediated immunity 
assessed by CSFE-LPA 
-Interaction between 
MAbs & different 
peptides from 
immune-dominant 
epitopes 
-Differences in 
intracellular 
mechanisms triggered 
by the infective 
particle or the inactive 
virus in murine 
dendritic cells (DC) and 
bovine afferent lymph 
DC 
-Colostral immunity & 
vaccination 
-VLPs using 
baculovirus-insect cell 
& mammalian cell 
transfection system  
-Novel adjuvants for 
pigs-matrix of soybean 
lecithin, cholesterol, 
glycans and saponins 
forming nanoparticles  
-Dendrimeric peptide-
based FMD vaccines in 
cattle 
-Baculoviruses as 
adjuvants assessed in 
mice 
-Enhancement of 
responses to DNA-
based vaccine by 
plasmids encoding 
CD40L and IL-15 
assessed in mice 
-RNAi-
based 
antiviral 
tools 
-Assess virus 
diversity, 
evolution & 
distribution 
during 2000/1 
outbreak 
-Validity of  
phylogenetics 
based on one 
sample per 
outbreak. 
  
IVI, 
Switzerland 
     -Improving FMD 
vaccines for cross-
protection, longer  
immunity and 
mucosal immunity 
    
116 
 
Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
IVRI, 
India 
-NSP ELISA with 3ABC 
protein expressed in 
insect cells using a 
baculovirus system 
-LFD test development 
-Relating results LPBE to 
VN 
   Vaccine 
-Baculovirus expression system for FMD 
vaccines 
-Reasonable guinea pig immune response to 
inactivated vaccine given with Toll-like 
receptor ligand, flagellin 
-Assess adenovirus vaccine comprising 
capsid coding sequences of Indian vaccine 
strains by serology and later challenge will be 
done 
Antivirals 
-Adenovirus vector produced 
IFNα and λ as therapeutics to 
control FMD at the early stage 
of infection 
-siRNA against FMDV 3C 
protease inhibited viral growth 
in BHK cells 
  
IZSLER, 
Italy 
-Develop monoclonal 
antibodies for ELISA kits, 
LFD, Luminex 
-ELISA for 146S 
measurement 
-SP antibodies to 
assess vaccine 
protection. 
-Harmonisation 
between 
laboratories 
-NSP & SP sero-surveys for endemic countries 
(issues-cross-reactivity, user-friendly kits and 
matching of field and tests strains, correlation 
with protection) 
-FMD structure & antigenic variability, 
epitope mapping    -Disinfecti
on in lab 
and field 
environm
ent 
LANAVET, 
Cameroon 
  -Epidemiology of strains in 
Cameroon 
       
LVRI, 
China 
-Improved diagnostics, 
including monoclonal 
ELISA & RT-LAMP 
(including for SAT 
viruses)  
-
Immunochromatographi
c strip with NSP MAb and 
dot-blot kits developed 
   -Understanding 
mucosal immunity 
Vaccines 
-Novel vaccines- nanoparticle-based nasal vaccine, epitope peptide 
vaccine, synthetic peptide vaccine, inactivated virus gene engineering 
based vaccine, and recombinant baculovirus capsid vector 
-Deleting an immunodominant epitope in NSP 3A for vaccine with 
complementary DIVA ELISA test 
-G-H loop epitope vaccine adjuvented with and polyinosinic-cytidylic 
acid 
-VLP with E,coli expression system 
 
NADDEC, 
Uganda 
-OIE twinning with Swedish Agricultural 
University        -Climate change 
resilience 
NaLIRRI, 
Uganda 
  - Investigating FMD Risk factors        
NARC, 
Pakistan 
-Develop RT-LAMP  -Understanding distribution of 
FMD in Pakistan 
-Role of persistently-infected 
water buffalo & cattle 
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Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
NCAD, 
Canada 
Diagnostics 
-Monoclonal antibodies for ELISA development-O typing 
-Monoclonal antibodies for serotype A cELISA & rapid tests 
-Polyspecific virus capture ApoH-ELISA for FMD & other vesicular 
diseases 
-Multiplex assay for detection of many swine viruses 
-FMD typing microassay 
Diagnostics 
-Assays adapted for portable, automated instruments 
-Genetic engineering  of cell lines for rapid replication 
of FMD virus for tests 
-Simplification of assays 
-Use of oral fluids for swine surveillance 
-146S ELISA to measure infectivity of culture 
     
  
NIAB, 
Pakistan 
-Use and evaluation of 
PCR & RT-LAMP 
         
NIBGE, 
Pakistan 
-IgM ELISA          
NVL, 
Pakistan 
-RT-PCR assays for 
detection and serotyping 
of local FMDVs 
      -Molecular 
epidemiology 
of regional 
FMD 
  
NVRI, 
Nigeria 
-Increasing diagnostic 
capacity 
 -Map FMD risk & strains & vaccine 
matching 
       
Ondespoort 
University, 
South Africa 
  -African buffalo behaviour & FMD 
risk 
       
OVI, 
South Africa 
 -Predict cross 
protection from 
capsid protein 
genetic & structural 
data +limitations of 
current matching 
methods 
-Identifying sites of 
antigenic drift for 
SAT1 viruses 
-How FMDV is maintained in 
buffalo populations & the role of 
concomitant disease and viral drift 
-Distribution, typing & vaccine 
matching of FMD in Uganda 
  -Reverse genetics 
to produce a SAT 
vaccine seed virus 
with capsid 
stability and cell 
culture adaptation 
mutations 
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Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
PIADC, 
USA 
-Infrared 
thermatography for 
early detection of FMD 
-Development of an 
inexpensive FMDV 
diagnostic kit based on 
camel monoclonal 
antibodies for sub-
Saharan Africa 
-Multiplex RT-LAMP to 
diagnose FMD and 
Vesicular Stomatitis, 
with a LFD readout 
format. 
-Determine 
challenge study 
protocols in sheep 
to assess vaccine 
protection and 
optimal route of 
vaccine application 
& dose 
-Determine 
immune correlates 
and assess 
protection from the 
adenovirus 
vectored FMD 
vaccine in cattle 
-Web-based FMD international 
surveillance platform (FMD 
Bioportal) 
-Modelling FMD transmission and 
evolution in the Lake Chad Basin 
-Transmission from carriers in the 
field 
-Phylogenetic, temporal and 
spatial analysis of viral strains 
circulating in Central Asia, 
Southeast Asia and Africa 
-Ecology & epidemiology in 
Cameroon, vaccine selection and 
supporting control 
-Ecology & epidemiology in 
Pakistan, vaccine selection and 
supporting control 
-
Understand 
host-
pathogen 
interaction 
-
Pathogenici
ty & 
transmissio
n of 
Korean201
0  isolates in 
pigs and 
cattle 
-Pathology 
of FMDV 
from 
persistently 
infected 
cattle and 
Asian 
buffalo in 
Pakistan & 
their role in 
transmissio
n 
-Define the immune 
response to infection 
& vaccination and 
identify genetic 
characteristics 
associated with 
animals with differing 
response 
-Analyse T cell 
responses to FMDV 
infection in swine and 
cattle 
-Import cells 
producing monoclonal 
antibodies specific for 
characterised bovine 
cells from ILRI, Kenya, 
and test for purity 
from pathogen 
contamination  
-Breed-specific 
responses to FMD 
infection and 
vaccination for vaccine 
development 
-Characterise host 
proteins that play 
critical roles in virus 
replication 
-Define events and cell 
type requirements 
leading production of 
FMDV-specific bovine 
Ig’s in vitro 
-Novel vaccines 
e.g. FMDVLL3B3D 
[see Zoetis] 
-Producing a 
recombinant 
vaccine seed virus 
with improved 
stability and cell-
culture growth 
and adaptation. 
-Improving cDNA 
technology and 
identification of 
epitopes to 
produce better 
matched 
recombinant 
inactivated 
vaccines for Africa 
 
-Unspecified 
antiviral 
research 
-Bio-
therapeutics 
targeting NK 
cells with 
cytokine 
expressing 
adenovirus 
vectors  
-Typing 
strains in 
Pakistan for 
use in 
vaccines 
-Typing 
strains in 
India for 
vaccine 
selection 
-Molecular 
epidemiology 
of FMDV in 
Vietnam 
-Molecular 
characterisati
on and 
distribution of 
FMD and 
training  in 
Uganda for 
vaccine 
selection 
 -Identify 
& 
evaluate 
chemical 
agents 
for viral 
inactivati
on  
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Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
Pirbright 
Institute, 
UK 
- Strain specific PCR 
-Pen side PCR 
-RT-LAMP 
-Improved ELISAs 
-Vaccine matching 
and strains for 
East Africa 
-Vaccine 
effectiveness 
evaluation 
-Modelling within & 
between farm 
transmission 
-Modelling within 
host dynamics 
-Viral receptors 
-Transmission mechanisms 
-Carriers & transmission & 
African buffalo 
-Picornavirus cell entry 
-CD4 T cells & FMD 
immunity 
-Identifying 
functionally important 
FMD antigens 
-Increased 
spectrum vaccines 
-Stable empty 
capsid vaccine 
 -Sequence evolution and 
transmission 
-Wildlife, 
control & 
trade needs 
-Safe trade 
protocols 
-FMD 
economic 
impact 
 
University of 
Glasgow, 
UK 
-Develop milk NSP test & 
PCR, use of virus 
sequence from milk to 
monitor FMD burden 
-Monitor vaccine field 
effectiveness 
-Diagnostics for East 
African stains & lab 
capacity in Africa 
 -Basic epidemiology of FMD in 
Tanzania including wildlife 
Immunology 
-Testing the immunodominance of 
antigenic sites and the contribution of 
different constituent amino acid 
residues by reverse genetics & use for 
vaccine matching 
-Identification of protective 
antibodies to capsid epitopes that 
protect against all serotypes [b cell 
epitopes, conserved epitopes] 
-Correlates of immunity for vaccine 
batch testing including T cell response 
-Improved 
vaccines for Africa 
& field evaluation 
-Novel adjuvants 
-
Matching/vaccine 
strain selection 
based on capsid 
gene sequence 
 Molecular 
-Develop tools/skills to use 
next generation sequencing 
to infer epidemiology & virus 
evolution, for understanding 
& tracing 
-Understanding how within-
host replication and 
transmission influence virus 
diversity and relationship 
with consensus sequencing 
and diversity along 
transmission chains 
 
University of 
Minnesota, USA 
 ` -FMD epidemiology in endemic countries 
-Modelling FMD in USA swine populations 
      
120 
 
Institute Diagnostics Vaccine 
Quality 
Assessment 
Epidemiology Pathogenesis Immunology Vaccines Antivirals Molecular 
biology Impact & trade Other 
University of 
Wageningen, 
Netherlands 
-NSP Ab blocking ELISA 
-Timing of NSP 
antibodies after 
infection or vaccination 
in cattle & small 
ruminants 
-Link between VNT 
& protection varies 
with dose & antigen 
-Vaccine 
selection/matching 
in Eritrea 
-Humoral & cellular 
immune correlation 
with vaccine 
protection  
-Harmonising tests 
used to predict 
efficacy 
-In vitro 
immunoassays to 
monitor NSP 
content and 
reduction during 
vaccine purification  
-Improved 146S 
quantification to 
asses vaccine batch 
quality 
-Environmental virus accounts for 
1/3 of transmission in housed 
cattle but nature of virus entry is 
unknown 
-Small ruminants are as 
susceptible as cattle but less 
infectious 
-Model implies 2-5 km ring 
vaccination can control an 
outbreak 
-Outbreak duration economically 
crucial so rapid 
control/vaccination needed 
-Serotypes in Africa/Eritrea 
-Assess FMD transmission in 
vaccinated buffalo  
-Gazelle & wild boar role in FMD 
transmission 
-Validate FMD control models 
assessing population data, 
sensitivity to poor/missing data-
different vaccination strategies  
-Future 
work will 
assess 
relation 
between 
genome 
and 
blocking of 
IFN 
responses 
-Virus 
excretion in 
different 
species- 
cattle, 
sheep, pig, 
buffalo, 
gazelle, 
wild boar 
-Timing of NSP 
antibodies after 
infection or 
vaccination in cattle & 
small ruminants 
-How to improve 
antibody response 
by changes in 
vaccine 
composition, dose 
& route of 
administration 
    
VLA, 
Tanzania 
  -FMD epidemiology & farmer 
awareness 
       
WCS-AHEAD, 
USA-
International 
  -Modelling risk of FMD product contamination along value chains 
-Modelling SAT serotypes and African Buffalo     
-Socio-economic & 
environmental impact of 
FMD on development 
and wildlife, including 
options for commodity-
based trade 
Zoetis, 
International 
-Complementary NSP 
ELISA for a negative 
marker vaccine  
    Vaccines 
-Inactivated recombinant FMD virus vaccine platform 
with a negative marker, that is non-virulent with  no 
transmission, with restriction sites to facilitate 
insertion of the capsid coding region of any serotype 
  
 
 
 
 
